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SUMÁRIO 
 
O termo osteoimunologia foi usado pela primeira vez em 2000 para 
descrever a interacção entre células do sistema imunitário e do osso. 
Estes dois sistemas têm vários factores em comum, tais como 
citocinas, factores de transcrição e receptores. Consequentemente, a 
sua interacção ocorre, não só em condições fisiológicas, mas também 
patológicas. O objectivo desta dissertação de doutoramento é o de 
compreender o efeito da inflamação mediada pelo sistema imunitário 
no comportamento estrutural, mecânico e biológico do osso usando a 
artrite reumatóide e a regeneração de fracturas como modelos. 
O primeiro estudo desta tese foca a análise do efeito da artrite no 
comportamento biomecânico do osso. Foi utilizado um modelo animal 
de artrite, o ratinho SKG, para avaliar o comportamento biomecânico 
do osso por testes de flexão de 3 pontos. A microscopia electrónica 
de varrimento e a microscopia multifotão foram utilizadas, 
respectivamente, para o estudo da estrutura óssea e da organização 
da rede de colagénio no osso trabecular. Os resultados deste estudo 
mostraram que o osso de ratinhos com artrite apresenta pior 
qualidade biomecânica comparando com os controlos. Observações 
por microscopia multifotão e microscopia electrónica de varrimento 
demonstraram alteração da organização do colagénio e da estrutura 
trabecular. Neste trabalho verificámos que a inflamação crónica per 
se conduz à degradação das propriedades biomecânicas, 
particularmente da rigidez, ductilidade e resistência. 
No mesmo modelo animal, prosseguimos com o estudo do efeito da 
inflamação no metabolismo e organização do colagénio. A avaliação 
do osso incluiu ensaios mecânicos, microscopia electrónica de 
varrimento, microscopia multifotão e doseamento de marcadores 
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séricos de remodelação óssea, especificamente o péptido amino-
terminal do procolagénio tipo I (P1NP) e o carboxi-terminal do 
telopéptido do colagénio tipo I (CTX). O osso dos ratinhos SKG 
revelou aumento da fragilidade óssea expresso pela deterioração das 
propriedades mecânicas. Em concordância, por microscopia 
electrónica de varrimento foi observado que a distância 
intertrabecular aumentou e a espessura trabecular reduziu e a 
microscopia multifotão demonstrou uma matriz desorganizada, com 
baixa densidade de colagénio. O metabolismo do colagénio foi ainda 
estudado no soro, encontrando-se aumentado nos ratinhos com 
artrite. Neste trabalho determinámos que o efeito de fragilidade 
óssea induzido pela artrite se deve à elevada remodelação óssea e 
desorganização da matriz de colagénio tipo I. 
Seguindo os dados iniciais obtidos em modelo animal, os primeiros a 
descrever o efeito directo da artrite na estrutura do colagénio e na 
biomecânica do osso, confirmámos e detalhámos estas observações 
em osso humano com artrite reumatóide. Foram recrutados doentes 
com AR submetidos a artroplastia da anca. A microarquitectura do 
osso trabecular foi avaliada por microtomografia computadorizada e o 
comportamento biomecânico por teste de compressão de um cilindro 
de osso trabecular extraído da epífise femoral. A actividade das 
células ósseas foi analisada através do estudo da expressão génica no 
microambiente ósseo. Observou-se um aumento da expressão dos 
genes que codificam citocinas pró-inflamatórias, particularmente a IL-
17, a qual desempenha um importante papel na estimulação da 
osteoclastogénese. O microambiente do osso com AR apresenta um 
perfil de expressão génico caracterizado pelo aumento das citocinas 
pró-osteoclastogénicas e de DKK1 e ainda do rácio de expressão 
RANKL/OPG. Paralelamente, verificou-se um aumento da expressão 
de factores indutores da actividade osteoblástica, tais como o IGF-I, 
FGF2 e PDGF, apesar da baixa expressão de colagénio tipo I. O DKK1 
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é um regulador negativo da via de sinalização WNT/β-catenina, sendo 
esta uma via chave na estimulação da diferenciação do osteoblasto. 
Assim, o aumento deste inibidor nos doentes com artrite reumatóide 
limita o efeito pró-osteoblastogénico do ambiente molecular do osso 
artrítico. A perda óssea associada às doenças crónicas inflamatórias, 
tal como a artrite reumatóide, parece, desta forma, resultar do 
aumento da reabsorção óssea e de uma diminuição na formação, 
conduzindo ao desequilíbrio da remodelação e precipitando a rápida 
perda de massa óssea. De facto, foram observadas diferenças na 
expressão génica entre o osso de doentes com artrite reumatóide e 
com osteoporose primária, apesar destes dois grupos de doentes 
terem microestrutura óssea e propriedades biomecânicas 
semelhantes. Estas observações parecem indicar que as diferenças 
encontradas a nível da expressão génica reflectem mecanismos 
biológicos específicos responsáveis pela fragilidade óssea na artrite 
reumatóide e a inibição do DKK1 poderá vir a ser uma possível 
estratégia terapêutica para diminuir os efeitos da artrite reumatóide 
sobre o osso. 
No último trabalho desta tese, utilizámos a reacção inflamatória pós-
fractura como modelo para caracterizar a cinética de expressão dos 
genes relacionados com a inflamação e remodelação óssea. Ao 
contrário da inflamação crónica, característica da artrite reumatóide, 
a regeneração de fracturas é um processo breve e cuidadosamente 
regulado. Foram incluídos neste estudo doentes submetidos a 
artroplastia da anca devido a fracturas de baixo impacto. Os doentes 
foram agrupados de acordo com o tempo decorrido entre a fractura e 
a cirurgia: osso colhido nos 3 dias após fractura, entre o 4º e o 7º 
dias, e uma semana após fractura. Um conjunto de genes 
relacionados com a inflamação e o metabolismo ósseo foram 
estudados no local de fractura. Os resultados obtidos indicam que a 
expressão dos genes relacionados com a inflamação, especialmente a 
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IL-6, estão aumentados nos primeiros dias após fractura; contudo, a 
partir do dia 4 verifica-se um desvio para os genes de remodelação 
óssea, sugerindo que a fase inflamatória activa a regeneração da 
fractura. A expressão da esclerostina, um inibidor da diferenciação do 
osteoblasto, está aumentada durante os primeiros dias após fractura 
e diminui após a redução da expressão dos genes pró-inflamatórios. 
Desta forma, propomos a existência de um processo em duas fases 
que conduz à regeneração de fracturas, dependente de um estímulo 
inicial inflamatório e uma diminuição subsequente dos efeitos 
relacionados com a esclerostina, com consequente estímulo 
osteoblástico. Assim, a indução local destes eventos poderá constituir 
uma intervenção promissora para acelerar a regeneração óssea após 
fractura. 
O trabalho aqui discutido claramente demonstra o complexo papel da 
inflamação na regulação óssea. A identificação de factores 
reguladores chave deste sistema será crucial para o futuro 
tratamento da artrite reumatóide e das fracturas. 
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SUMMARY 
 
The term osteoimmunology was used for the first time in 2000 to 
describe the interaction of cells from the immune system and bone 
These two systems have several regulatory factors in common, such 
as cytokines, transcription factors and receptors. Consequently, they 
interact with each other both in physiological and pathological 
conditions. The aim of this dissertation thesis was to understand the 
effect of immune mediated inflammation on bone structural, 
mechanical and biological behaviour, using rheumatoid arthritis (RA) 
and fracture healing as a model. 
The first study of this thesis focused on the analysis of the effect of 
arthritis on bone biomechanical behavior. An animal model of 
arthritis, the SKG mice, was used and bone behavior was evaluated 
by mechanical three-point bending tests. Scanning electron 
microscopy (SEM) and multiphoton microscopy (MPM) were applied to 
study, respectively, bone structure and the collagen network 
organization in trabecular bone. Results from this study have shown 
that arthritic bones had poor biomechanical quality compared to 
control bones. MPM and SEM observations disclosed signs of impaired 
collagen organization and poor trabecular architecture. In this work 
we verified that chronic inflammation per se leads to impairment of 
bone biomechanics in terms of stiffness, ductility and ultimate 
strength. 
In the same model, we then proceed to study the effect of 
inflammation on collagen metabolism and organization. The 
evaluation of bone included mechanical tests, SEM, MPM and serum 
bone turnover markers, specifically procollagen type - amino-terminal 
peptide (P1NP) and carboxy-terminal crosslinked telopeptide of type I 
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collagen (CTX). Femoral bones of SKG mice revealed increased 
fragility expressed by deterioration of mechanical properties. In 
accordance, as observed by SEM, intertrabecular distance was 
increased and trabecular thickness decreased. MPM depicted a 
disorganized matrix and loose collagen structure compared to 
controls. Moreover, the collagen metabolism assessed in the serum 
was also highly increased in arthritic mice. In this work we found that 
the bone weakening effect of arthritis was due to high bone turnover 
and disorganized collagen type I matrix. 
Following these initial animal model data, the first to describe a direct 
effect of arthritis on collagen structure and bone biomechanics, we 
confirmed and further detailed these observations in human RA bone. 
Patients with RA submitted to hip replacement surgery were 
recruited. Trabecular bone microarchitecture was assessed by micro-
computed tomography (microCT) and mechanical behavior by 
compression tests of a bone cylinder extracted from the femoral 
epiphysis. Bone cell activity was analyzed by studying gene 
expression in the bone microenvironment. Genes that code for pro-
inflammatory cytokines were upregulated in RA patients, particularly 
IL-17, which plays an important role in stimulating 
osteoclastogenesis. RA bone microenvironment had a gene 
expression profile characterized by upregulated pro-osteoclastogenic 
cytokines and dickkopf homolog 1 (DKK1) and increased RANKL/OPG 
ratio. This was paralleled by raised expression of factors that promote 
osteoblastic activity, such as IGF-I, FGF2 and PDGF, but with low type 
I collagen expression. DKK1 is a negative regulator of the WNT/β-
catenin signaling, which is a key pathway in the stimulation of 
osteoblast differentiation, meaning that its upregulation in RA 
patients is limiting the effects of pro-osteoblastic factors. Bone loss in 
a chronic inﬂammatory disease, such as RA, thus appears to result 
from enhanced bone resorption and impaired bone formation, which 
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constitutes a detrimental imbalance of bone remodeling and 
precipitates the rapid loss of bone mass. Indeed, differences were 
observed in gene expression between RA and primary osteoporosis 
(OP) bone in spite of the fact that these two patient groups had 
similar bone microarchitecture and biomechanical properties. These 
observations might indicate that the differences in gene expression 
reflect biologically specific mechanisms responsible for bone fragility 
in RA and that the inhibition of DKK1 can be a possible treatment 
strategy for tackling the effects of RA on bone. 
In the final work of this thesis, we have used the post-fracture 
inflammatory reaction as a model for characterizing the kinetics of 
inflammatory and bone remodeling related genes. Unlike the chronic 
inflammation seen in RA, fracture healing is a highly regulated and 
brief process. Patients submitted to hip replacement surgery after a 
low-energy hip fracture were enrolled in this study. Patients were 
grouped according to the time interval between fracture and surgery: 
bone collected within 3 days after fracture; between the 4th and 7th 
day; and one week after fracture. Inflammation and bone metabolism 
related genes were assessed at the fracture site. Our results indicate 
that the expression of inflammation related genes, especially IL-6, is 
highest at the very first days after fracture but from day 4 onwards 
there is a shift towards bone remodeling genes, suggesting that the 
inflammatory phase triggers bone healing. Sclerostin expression, an 
inhibitor of osteoblast differentiation, has an initial high expression 
level that is diminished after the reduction of inflammatory gene 
expression. We propose the existence of a two step process in bone 
healing, dependent on an initial inflammatory stimulus and a latter 
decrease in sclerostin-related effects, with a consequent pro-
osteoblastic effect. Therefore, local promotion of these events might 
constitute a promising medical intervention to accelerate fracture 
healing.  
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The work herein discussed clearly shows that inflammation has a 
complex role in bone regulation. The identification of key regulators 
of this system will be crucial both for RA and fracture healing future 
management. 
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BONE 
 
Bone is one of the most dynamic human tissues, as it remains 
metabolically active throughout life and has pleiotropic functions in 
the organism. It not only protects the internal organs, supports the 
body and assists in its movement but also function as a mineral 
(calcium and phosphorus) and fat reservoir and harbours bone 
marrow, where haematopoiesis occur.  
Bone is composed of three different cell types: osteoclasts, 
osteoblasts and osteocytes. These cells are responsible for the daily 
bone renewal in a tightly balanced process. On the other hand, the 
organization of bone as a tissue is dependent on complex interactions 
between three main players; collagen type I, hydroxyapatite crystals 
and cells. 
From a structural perspective bone can be classified in hierarchical 
levels of complexity, all of which affect its mechanical properties. It 
must be stiff, slightly flexible and light in order to make loading 
possible and facilitate movement.  
Additionally bone has a unique characteristic that distinguishes it 
from other tissues: it can respond according to the location and 
extent of the biomechanical loading and microdamage, remove the 
damaged tissue and replace it with new bone. Disequilibrium of this 
system is observed in bone metabolic diseases, such as primary 
osteoporosis (OP), or as consequence of systemic inflammatory 
diseases such as rheumatoid arthritis (RA). This will induce bone 
fragility and eventually low energy fractures.  
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How inflammation affects bone structure and mechanics and how 
different are the processes that occur in RA and OP are issues still not 
completely understood. In order to address these questions a 
comprehensive knowledge on bone structure, mechanics and biology, 
coupled with an understanding of the crosstalk between the immune 
system and bone is essential.  
 
 
BONE STRUCTURE 
At the macroscopic structural level, bones have diverse shapes 
accounting for the different supporting and/or protective functions 
they play. In the appendicular skeleton we can find long bones which 
provide stability against bending and buckling. Bone is covered by a 
shell, the cortical bone, which is filled in by a honeycomb-like 
structure, the trabecular bone2. Trabecular bone absorbs energy and 
is light and flexible. The cortical structure, on the other hand, has the 
ability to tolerate the peak loads that the long bones are subjected 
to3. 
Cortical bone is quite dense, with a porosity of only about 6%, mainly 
due to the presence of blood vessels. In fact, this type of bone is 
characterized by the presence of structures called osteons, 
comprising a blood vessel surrounded by concentric layers of bone, 
which form the Haversian system. Therefore, cortical bone consists of 
overlapping parallel osteons that block the propagation of 
microcracks. On top of that, damage propagation into the osteon is 
blocked by its surrounding cement line3-4, which delimits each osteon, 
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and by the concentric lamellae of mineralized collagen fibers3. Cortical 
bone contains Haversian and transversal Volkmann canal systems for 
vascular supply. These structures are surrounded by 5 to 15 
concentric lamellae several microns thick with its fibers aligned 
parallel to each other, around the vascular canal. Haversian canals 
contain capillaries and small blood vessels, lymphatic vessels and 
connective tissue with osteoprogenitor cells. On the other hand, 
Volkmann canals are vascular channels which link the periosteum and 
bone5. 
Trabecular bone is composed of trabeculae arranged in a honeycomb-
like network, which confers a porosity of about 80%. Each trabecula 
has a thickness of around 200μm and their orientation depends on 
load distribution. Trabeculae are surrounded by bone marrow and 
fat2. The trabecular structure is characterized by the number of 
trabeculae in a given volume of bone, their thickness as well as the 
distance and connectivity between them. Previously, observation of 
trabecular microarchitecture was only possible by two-dimensional 
histomorphometry but nowadays, new imaging techniques such as 
high-resolution microcomputed tomography (microCT), allow tri-
dimensional observation of bone microstructure6. Trabecular bone is 
metabolically more active than cortical bone and this is why studies 
on bone quality have mainly focused on this component of bone. 
Regarding collagen fiber arrangement, bone can be classified in 
woven bone and lamellar bone. In woven bone, which is 
predominantly present during fetus development, bone collagen 
fibers are randomly oriented and there are higher numbers of cells 
per unit area than in mature bone. In adults, woven bone can only be 
found in areas where bone is being remodeled. Lamellar bone, the 
mature form of bone, develops when the deposition rate is slow and it 
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has a well-organized arrangement of collagen fibers. In general, it is 
formed only over pre-existing bone, either woven or lamella5. 
 
 
BONE MATRIX 
 
Bone matrix is composed of two components, an organic phase 
(about 40% of the dry weight) made up of collagen, proteoglycans, 
glycoproteins, phospholipids and phosphoproteins, and an inorganic 
phase (about 60% of the dry weight) of calcium hydroxyapatite 
(Ca10(PO4)6(OH)2)5. 
 
COLLAGENS 
Collagens are a group of natural occurring proteins that share 
common features. The widely accepted definition of collagen is 
“structural proteins of the extracellular matrix which contain one or 
more domains harboring the collagen triple helix”7-8. About 90% of 
bone matrix is composed of type I collagen that undergoes 
posttranslational modifications specific to this tissue. These 
modifications (hydroxylation and glycosylation) partly explain why 
mineralization only occurs in bone and not in other tissues9.  
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The collagen fibril is the basic unit of bone matrix. This fibril results 
from the junction of 300nm long and 1.5nm thick collagen monomers 
which are produced by osteoblasts10. Each type I collagen molecule is 
composed of a repeating tripeptide sequence (Gly-X-Y) that form a 
left-handed helix containing two pro-α1 and one pro-α2 chains11. The 
three chains assemble in a right-handed triple helix, where the Gly 
residues are in the center and the lateral chains of X and Y are on the 
surface of the helix8. In the most common occurring triplets 
(10.5%)12, X is a proline and Y is a hydroxyproline (Gly-Pro-Hyp), 
which is a unique characteristic of collagen and it is essential to 
stabilize the triple helix. These fibrils have high tensile strength and 
play a pivotal role in providing structural support for body structures, 
such as the skeleton, skin, blood vessels, intestine and fibrous 
capsules of organs13. In humans the α1 chain is coded by a gene 
located on chromosome 17 (17q21.3-q22), while the α2 chain is 
located on chromosome 7 (7q21.3-q22). Each messenger RNA 
(mRNA) is monocistronic14 and several growth factors and hormones 
regulate with collagen synthesis at the transcriptional level. The Sp1 
transcription factor (SP1)15 and runt-related transcription factor  
(RUNX) 216, among others, bind to the promoter regions controlling 
collagen type I gene transcription. Several other factors contribute to 
the expression of this protein, either by modulating its mRNA levels 
or by stabilizing it. Transforming growth factor (TGF)β17-18, insulin-
like growth factor (IGF)-I18-19 and interleukin (IL)-620 have been 
found to stimulate collagen mRNA synthesis while tumor necrosis 
factor (TNF)21, interferon (IFN)γ22, IL-123, parathyroid hormone 
(PTH)24 and the active form of vitamin D325 suppress it. 
After transcription, the pre-mRNA undergoes maturation by exon 
splicing, capping, and addition of a poly(A) tail. These mRNAs are 
translated and the resulting proteins undergo extensive post-
translational modifications before being assembled in a triple helix 
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and released to the extracellular space. Both the pro-α1 and the pro-
α2 chains undergo hydroxylation of proline to hydroxyproline, and 
glycosylation, which are the two critical modifications to obtain a 
stable triple helix. The triple helix formation is then started at the 
carboxy-terminal end of the molecule and extends towards the 
amino-terminal end7. Procollagen is thereafter secreted to the 
extracellular space where specific enzymes [a disintegrin-like and 
metalloproteinase (reprolysin type) with thrombospondin type 1, 
motif 2 (ADAMTS2) and bone morphogenetic protein (BMP)-1] cleave 
the propeptides, giving rise to mature collagen molecules which 
triggers spontaneous self-assembly of the collagen molecules into 
fibrils. The processed collagen monomers within fibrils are joined by 
covalent cross-links which mature with aging26-27. Cleavage of the 
propeptides reduces the solubility of the molecules and therefore a 
major extracellular function of carboxy propeptides is to prevent 
premature fibril formation, while the amino propeptides influence 
fibril shape and diameter27. 
The final assembly of fibrillar collagen involves the interaction with 
several proteins that have a role in the organization of the matrix 
pattern and control the diameter of the fibrils28-29. Of interest, 
biglycan and decorin, two proteoglycans highly expressed in 
extracellular bone matrix, interact with collagen molecules to 
facilitate fibril formation, which will later allow mineral deposition30.  
In clinical practice, products of the collagen processing or breakdown, 
either for the formation or degradation, act as markers of collagen 
turnover and are used to assess bone remodeling31. Collagen type I 
propeptides, amino-terminal (P1NP) and carboxy-terminal (P1CP) 
result from posttranslational cleavage of the pro-collagen molecule 
before its organization in fibrils32. The propeptides P1NP and P1CP are 
two small domains present in the procollagen molecule, which after 
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secretion of the molecule into the extracellular space are 
enzimatically cleaved. Since both propeptides are stochiometrically 
produced from each new collagen molecule, P1NP and P1CP are 
considered quantitative measures of collagen formation. Moreover, 
P1NP serum levels correlate with bone formation indices assessed by 
histomorphometry33. The strength of the collagen fibers depends on 
the formation of covalent cross-links between the telopeptides and 
the adjacent helical domains of collagen molecules. The cross-linked 
telopeptides of type I collagen, amino (NTX) and carboxy-terminal 
(CTX), are products of the collagen cleavage. Both NTX and CTX are 
products of cathepsin K (CTSK) action and represent collagen 
breakdown. CTX contains epitopes prone to spontaneous 
isomerization: α-CTX is the native sequence, while β-CTX represents 
collagen maturation through translocation of an aspartic acid residue 
from position α to β. Therefore, the ratio α/β-CTX is an indicator of 
bone age, the lower the ratio, the older the bone34. As CTX, 
pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen (ICTP) 
is also a product of collagen breakdown. ICTP epitope neighbors CTX but it is 
released as a result of MMP activity35 and it measures a relatively large 
hydrophobic phenyl-alanine rich pyridinolines cross-link of the two α1 chains in 
the carboxy-terminal of matured collagen type I. However, since the helical part 
of the α-chain is strongly conserved among different types of collagen, the 
specificity of this marker in reflecting bone resorption is not the best33. 
 
NON-COLLAGENOUS PROTEINS 
Although bone matrix is composed mostly of collagen, other non-
collagenous bone proteins have been described since 197436. Non-
collagenous proteins, including osteopontin (OPN), bone sialoprotein 
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(BSP), osteonectin, osteocalcin (OCL), and proteoglycans may have a 
regulatory function controlling the size and orientation of deposited 
minerals. Through sequestration of calcium or enzymatic release of 
phosphate from these proteins, they may act as a reservoir for 
hydroxyapatite crystals formation37. Collagen acts as a scaffold for 
mineralization and these non-collagenous proteins are the nucleators 
of hydroxyapatite crystals13. 
Biglycan and decorin are two proteoglycans that are found in several 
tissues. In bone they contain chondroitin sulfate chains and bind to 
collagen fibers38. Biglycan is upregulated in osteoblasts and its 
expression is maintained in osteocytes. On the other hand, decorin is 
expressed during the preosteblast stage, maintained in fully mature 
osteoblasts and is downregulated when the cells differentiate towards 
the osteocyte phenotype13. As osteocytes probably act as bone 
mechanoreceptors39, biglycan may act as transducer of shear forces 
within canaliculi. Biglycan-deficient mice are normal at birth but 
evidence reduced growth and bone mass, together with deterioration 
of bone biomechanical behavior by  the third month of life40. Proving 
a relevant role of biglycan/decorin in bone biology, a double-knockout 
mouse for these proteins has severe osteopenia with alterations in 
the geometry of the bone collagen fibrils41.  
Osteonectin is a glycoprotein secreted by the osteoblast that binds 
collagen, calcium and hydroxyapatite. It is hypothesized that this 
molecule plays a role in the nucleation of hydroxyapatite crystals42. It 
regulates cell proliferation and stimulates angiogenesis and 
metalloproteinase production43. Osteonectin-deficient mice show 
decreased bone remodeling leading to severe osteopenia in older 
animals. Moreover, the bone of these mice is characterized by 
decreased trabecular connectivity and decreased mineral content but 
with increased hydroxyapatite crystal size44-45. 
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Osteopontin is a member of the family of small integrin-binding 
ligands with N-linked glycosylation (SIBLING). This protein is 
expressed in several tissues, including bone, kidney and the immune 
and vascular systems. In bone it promotes osteoclast binding to the 
extracellular matrix and activates intracellular signaling pathways43, 
46. Osteopontin is produced at the late stage of osteoblast maturation 
during matrix formation and mineralization47. Osteopontin-deficient 
mice develop normally but are resistant to ovariectomy-induced bone 
resorption. Moreover, these mice have increased mineral content 
although the crystals are smaller than in wild-type mice48. 
BSP, like osteopontin, contains both mineral and integrin-binding 
sites. It is expressed by hypertrophic chondrocytes, osteoclasts and 
mature osteoblasts49. In osteoblasts, induction of BSP expression 
coincides with the initiation of mineral deposition and this protein is 
upregulated by factors that induce osteoblast differentiation50. BSP is 
located at the mineralization front and, based on its affinity for 
collagen, it is believed to be a nucleator for crystals51.  
Osteocalcin is exclusively expressed in bone and dentin. It is a 
calcium-binding protein characterized by three gamma-
carboxyglutamic acid residues. Due to its interaction with 
hydroxyapatite it is believed that OCL regulates the growth and 
maturation of bone crystals43. In fact, OCL measurements in serum 
have proven to be a valuable marker for bone turnover in metabolic 
bone diseases31. 
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HYDROXYAPATITE CRYSTALS 
In 1964, Hodge and Petruska52 proposed the now widely accepted 
model for the mineralization of collagen in bone structure. In this 
model, collagen fibrils are coated with mineral crystals, arranged 
parallel to each other and to the axis of collagen fibrils. Crystal 
formation is triggered either by deposition of collagen or non-
collagenous proteins that act as nucleation centers. After nucleation, 
crystals are elongated and, later on, grow in thickness. This very 
orderly process is crucial for bone nano-organization and resistance; 
disturbances in collagen conformation lead to bone fragility, such as 
osteogenesis imperfecta, where a mutation in the collagen gene 
occurs53. 
Bone crystals are composed of carbonate apatite mineral, called 
dahllite, which has hexagonal crystallographic structure, although 
crystals do not express this symmetry in their macroscopic shape. 
Instead, they assume the form of plates or tablets54. The plate-like 
crystals arise in the discrete spaces within the collagen fibrils, thereby 
limiting crystal growth and forcing it to be discrete and discontinuous. 
Crystals grow in such a way that their axis is roughly parallel to the 
long axis of the collagen fibrils55-57. 
The endpoint for matrix mineralization is the deposition of crystals 
between collagen fibers, a process that comprises two phases, an 
initial formation of apatite crystals within matrix vesicles and a 
subsequent propagation phase within the matrix. In the first phase of 
crystal formation, the ions that will later constitute the crystals form 
a cluster with the correct orientation, giving rise to a stable structure. 
This nucleation is facilitated by an increase in the local concentration 
of ions which increases the probability of association58. The initial 
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phase of mineralization occurs inside matrix vesicles. These are 
released by budding from the surface of osteoblasts but have a 
special membrane composition59 being enriched in alkaline 
phosphatase, nucleotide pyrophosphatase, phosphodiesterase, 
annexins and phosphatidyl serine60-61. It was proposed that the 
vesicle lipids could act as nucleation center for hydroxyapatite 
formation62-63. The minerals inside the vesicle precipitate initiating the 
formation of hydroxyapatite crystals that penetrate the membrane 
and give rise to calcification nodules in the extracellular fluid during 
the propagation phase of matrix mineralization64-65. The mineral 
crystals subsequently proliferate within and between the collagen 
fibrils66.  
Both collagen and non-collagenous proteins regulate the expansion of 
crystals, while cells can affect their maturation status58.  
 
 
BONE IMAGING 
During the last 10 years high-resolution imaging techniques have 
been introduced for assessing bone quality parameters, primarily for 
research proposes. The new imaging studies provide information on 
bone morphometry, microarchitecture and on the relationship 
between bone microarchitecture and strength. Moreover these new 
imaging tests have proved to be useful for assessing the effect of new 
treatments. 
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Through radiography, the most common method to visualize bone, 
cortical and trabecular compartments are observed in a two-
dimension (2D) format with a spatial resolution up to 40µm. Although 
this is a 2D image method, texture analysis parameters can be 
applied and have shown good correlation with three-dimension (3D) 
bone microarchitecture67, biomechanical properties68 and with several 
histological characteristics69. During the last 20 years, dual-emission 
X-ray absorptiometry (DXA) has been the most widely used method 
for measuring bone mineral density (BMD). Recent advances in DXA 
include software that calculates several other structural parameters 
that are important to determine bone fragility, such as hip-axis 
length, femoral neck cross-sectional area, moment of inertia and 
femoral neck shaft angle. The conventional method for evaluating 
bone microarchitecture is histomorphometry and stereology. In 1987, 
Parfitt developed and published70 standardized nomenclature for 
histomorphometry parameters, reflecting trabecular size and spacing, 
as well as porosity. Through this technique bone is evaluated at a 
resolution of 1µm, although a biopsy is needed and three dimensional 
analysis is only achieved by serial sections of the tissue71.  
Computed tomography (CT)-based techniques have several 
advantages over the other bone imaging techniques. In contrast to 
DXA, volumetric quantitative CT (vQCT) offers 3D information of 
cortical and trabecular bone that can be separately analyzed. 
Currently, the imaging of specimens, bone biopsies and small animals 
for bone structure investigation is almost exclusively done with 
microCT. X-ray computed CT is an imaging technique that uses 
ionizing radiation and a method employing tomography created by 
computer processing. Digital geometry processing is used to generate 
a three-dimensional image of bone from a large series of two-
dimensional X-ray images taken around a single axis of rotation72.  
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Bone vQCT measurements are reported as true volumetric density. 
This technique can be used in vivo and trabecular and cortical bone 
can be evaluated separately. Moreover, vQCT is more sensitive than 
DXA in the detection of density differences73-74 and can, thus, analyze 
both densitometry and geometrical components either of the entire 
bone or its cortical and trabecular compartments separately74. This 
technique also allows understanding how proximal femoral structural 
parameters explain bone strength, independently of BMD75. Recently, 
peripheral vQCT has been used for the evaluation of 
microarchitecture of the radial bone76. 
Until recently, bone histomorphometry was the standard for 
assessing trabecular and cortical architecture. Although this analysis 
provide unique information on cellularity and dynamic indices of bone 
remodeling, it has limitations with respect to assessment of bone 
microarchitecture, because structural parameters are derived from 
stereologic analysis of consecutive 2D sections, usually assuming that 
the underlying structure is plate-like70, 77. MicroCT, with a spatial 
resolution of 1 to 100µm, promises to replace histomorphometric 
analysis and allows the possibility of repeated in vivo investigation in 
small animals and human beings72. The accuracy of microCT 
morphology measurements has been compared with traditional 
measures from 2D histomorphometry both in animal78 and in 
human79-80 specimens. These studies showed that 2D and 3D 
measurements by microCT generally highly correlate with those from 
2D histomorphometry. Therefore, microCT offers numerous 
advantages in the assessment of bone morphology ex vivo: it allows 
direct 3D measurement of trabecular morphology, such as trabecular 
thickness and separation; compared with 2D histology, a larger 
volume of interest can be evaluated; measurements can be 
performed with a much faster throughput and assessment of bone 
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morphology by microCT scanning is non-destructive, thus, samples 
can be used subsequently for other assays77. 
Magnetic resonance imaging (MRI) reaches 150µm resolution and has 
several advantages other than assessing bone quality, namely the 
lack of ionizing radiation and the ability to investigate beyond bone 
structure, such as marrow fat content, diffusion and perfusion81. 
However, MRI acquisition is slower and technically more demanding 
than microCT. In addition, it is also much more expensive. 
The scanning electron microscope (SEM) uses a focused beam of 
high-energy electrons to generate a variety of signals at the surface 
of solid specimens. The signals that derive from electron-sample 
interactions reveal morphology (texture) of the sample, chemical 
composition and crystalline structure. Areas ranging from 
approximately 1cm to 5µm in width can be imaged in a scanning 
mode using conventional SEM techniques (magnification ranging from 
20X to approximately 30.000X, spatial resolution reaching 50 to 100 
nm). Due to the very narrow electron beam, SEM micrographs have a 
large depth of field yielding a characteristic 3D appearance useful for 
understanding the surface structure of a sample. SEM analysis is 
considered to be "non-destructive"; that is, X-rays generated by 
electron interactions do not lead to volume loss of the sample, so it is 
possible to analyze the same samples repeatedly82. This technique 
enables the observation of the tissue topography in high-resolution 
images and has proven effective in the investigation of the activity of 
bone surfaces83-84. SEM is effective for the analysis of hierarchical 
composite structure and surface topography induced by microdamage 
accumulation and fracture due to its high resolution and large depth 
of field85. SEM has been used extensively to study the damage 
accumulation and fracture behavior of bone86.  
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Multicolor non-linear microscopy of type I collagen arrangement can 
be obtained using second-harmonic generation (SHG) and two-
photon excitation (TPE). SHG arises when the electric field of the 
exciting light is strong enough to deform a molecule. When this 
molecule is not symmetrical, such as the collagen superhelix, the 
resulting anisotropy creates an oscillating field with twice the energy, 
twice the frequency and half the wavelength, the so-called second 
harmonic. SHG microscopy is a powerful tool that has been developed 
to assess collagen with a high spatial resolution87-88 and has already 
been applied to eye89, teeth90, tendons91-92, cartilage93, synovial 
membrane94, wound repair95, lung fibrosis96 and metastatic growth97-
98. In fact, spectral differences in the second-harmonic signal from 
normal and cancerous tissue have been described, opening up a 
possibility that might become a useful diagnostic tool in oncology99-
102. A correlation between SHG intensity, fibrilar morphology, 
polarization anisotropy and signal orientation with impaired 
mechanical strength has been reported in osteogenesis imperfecta, a 
bone disease resulting from mutations in the collagen gene103. SHG 
microscopy offers also the possibility of providing submicrometer 3D 
spatial resolution images without the need for tissue processing or 
stain104. The signal is acquired by two opposing detectors, the 
backward-SHG channel detects the backscattered SHG signal and the 
forward-SHG channel receives the photons that are transmitted 
through the sample105. The development of quantitative SHG 
microscopy for clinical applications and studies will require the use of 
the backward SHG signal; therefore, is of major importance to 
understand this information. The forward/backward ratio has been 
used to access the thickness of fibril shells and the ionic strength of 
the surrounding medium106. In tendon, sclera and ear cartilage the 
preferred orientation of the collagen fibers was analyzed in both 
channels92. Moreover, multiphoton microscopy has become a 
powerful method for non-invasive high-resolution in vitro, in situ and 
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in vivo imaging of extracellular matrix structures and cells in living 
intact native and tissue-engineered tissues107. Microendoscope 
prototypes have already been developed and applied to small animal 
research108 and in dermatology as a method for noninvasive skin 
cancer detection105, 109. A study in collagen fibrils from tendon 
samples suggested that the forward-SHG channel reflects essentially 
the mature polymerized collagen and the backward-SHG channel 
represents the immature collagen fibril segments, indicating ongoing 
fibrilogenesis106. 
 
 
BIOMECHANICS OF BONE 
In 1869 Julius Wolff, a German anatomist and surgeon, stated that 
bone adapts in response to the mechanical loads applied on it. More 
than one hundred years later we still believe that bone, as a natural 
material, has evolved and adapted to fill the needs posed by the 
function it exerts. Many of these needs are mechanical, such as the 
need to support static and dynamic loads created by the weight of the 
organism and the need to be resistant to fracture110. 
The bone mechanical properties describe the relationship between 
applied forces, or loads and bone deformation. The resistance of bone 
in response to these forces is known as stress and represents the 
intensity of the local force. The resultant deformation is referred to as 
strain and is defined as a relative change in size or shape. Normal 
strains represent elongation or shortening while shear strains 
represent distortion. Therefore, a load-deformation curve or a stress-
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strain curve are often used to define the biomechanical properties of 
bone13. 
The load-deformation curve (figure 1) reflects the structural behavior 
of bone and describes the amount of load needed to produce a unit of 
deformation. The analogous stress-strain curve reflects the material 
behavior of bone tissue and this curve is generated through a 
mechanically standardized (size and shape) test. Load and 
deformation have a linear relationship until the yield point is reached; 
at this time the slope of the curve is reduced. Before the yield point 
the material obey the Hooke’s law which states that there is a 
proportional relationship between stress and strain. This linear 
relationship is translated by the Young’s modulus, or bone stiffness, 
that measures the resistance of the bone to deformation5, 111. The 
yield point is the cross point of transition from an elastic behavior to 
a plastic one and corresponds to the occurrence of the first 
microfractures in bone tissue. If the bone is unloaded in the elastic 
region it returns to its original shape with no remaining deformation, 
while in the plastic region the load leads to permanent plastic 
deformations. If the bone continues to be loaded the ultimate or 
failure load is reached, after which the structure fails catastrophically 
(the bone fractures). Therefore, the slope of the elastic region defines 
bone stiffness while the strain energy, or toughness, is the energy 
required to initiate failure of the structure and is computed as the 
area under the curve13, 111. Through the analysis of the stress-strain 
curve several material characteristics can be established. A material 
is brittle when it only exhibits elastic deformation such as is the case 
with polymethylmethacrylate. On the other hand, a ductile material 
undergoes a large amount of plastic deformation before failure, like 
metals. In viscoelastic materials the stress-strain behavior is 
dependent on the time and rate of loading; these materials exhibit 
both fluid and solid-like properties with gradual deformation and 
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recovery when subjected to loading and unloading. The response of 
viscoelastic materials is dependent on how quickly the load is applied 
or removed and the extent of deformation is dependent on the rate at 
which the deformation-causing loads are applied. On the other hand, 
a constantly maintained deformation will cause stress relaxation, that 
is, the force required to maintain the deformation diminishes with 
time. The stress-strain relationship for viscoelastic materials is a 
function of time rate at which the stress and strain are applied in the 
material. Biologic tissues such as articular cartilage, intervertebral 
disc, ligament, tendon and fresh bone all show a viscoelastic 
behavior5, 112. 
 
 
Figure 1 – Graphical representation of the structural behavior of a material. 
The relation between stress and strain, represented by the stress-strain curve (A), 
is reflected by the Young’s modulus, or stiffness, that measures the bone resistance 
to deformation while the toughness is the energy required to induce failure of the 
structure and is computed as the area under the curve. The yield point is the cross 
point of transition from an elastic behavior to a plastic one and corresponds to the 
occurrence of the first microfractures. After this point, if the structure continues to 
be loaded the ultimate load or failure load is reached, after which a fracture will 
occur. This same curve also allows us to distinguish between ductile and brittle 
materials (B). The ductility of a material is a measure of the extent of which a 
material will deform before fracture. On the opposite, when a brittle material 
reaches the limit of its strength, fracture occurs. Therefore, while a ductile material 
undergoes large amounts of plastic deformation before fracture, a brittle material 
curve only exhibits elastic region. 
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Bone is a composite of hydroxyapatite crystals dispersed in a collagen 
matrix. Collagen is tough but not very stiff; on the other hand 
minerals are stiff but not very tough. Therefore, the mineral phase 
dominates the stiffness of bone and the toughness of the material 
arises from its hierarchical structure110. The toughness of the material 
increases with decreasing mineral content and increasing collagen 
content113. Bone stiffness is intermediate between that of 
hydroxyapatite and collagen, while its strength is higher than that of 
either components111. Therefore, bone combines the best properties 
of mineral and protein content, it is stiff to prevent bending and 
buckling, but it is also tough in order to avoid fracture when the load 
exceeds the normal range2, 110.  
The two types of bone, cortical and trabecular, also show different 
biomechanical performance. Cortical bone is stiffer than trabecular 
bone, resisting to higher stress but lower strain before failure. Due to 
its porous structure trabecular bone has a large capacity for energy 
storage112. Both cortical and trabecular bone mechanical properties 
are dependent on bone density114. In fact, studies have shown that 
density explains 60% to 90% of the variation in bone strength and 
stiffness115 and that small changes in bone density lead to remarkable 
changes in mechanical behavior116. However, the correlation between 
bone mineral density assessed by DXA and bone strength is relatively 
low117. Cortical and trabecular bone are anisotropic materials since 
their mechanical properties depend on the loading direction. This 
characteristic reflects bone function and we can find higher strength 
and stiffness in the primary loading direction2, although the degree of 
anisotropy varies with anatomical site and functional loading118. Bone, 
as a natural material, shows large variability in its mechanical 
behavior113, in fact, mechanical properties of trabecular and cortical 
bone types vary from one bone to another and even within different 
regions of the same bone119-120. 
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In vivo, bone is subjected to several different loading modes 
producing tension, compression, shear, bending, torsion and 
combined loading. During tensile loading the forces are directed away 
from the surface of the structure, leading to lengthening and 
narrowing. Fractures produced by tensile loading are typically seen in 
bones with a large proportion of trabecular bone. In compressive 
loading, equal and opposite loads are applied towards the surface of 
the structure, leading to shortening and widening. Clinically, fractures 
produced by compressive forces are found in the vertebrae, especially 
in the elderly with osteoporotic bone tissue. During shear, loading 
forces are applied parallel to the structure and shear stress and strain 
develop inside the structure. Therefore, the shear load deforms in an 
angular manner. Fractures that result from this loading are often 
seen in trabecular bone. In bending, a combination of tensile and 
compressive loads is applied in such a way that causes the structure 
to bend. Bending tests can be produced by three (three-point 
bending) or four (four-point bending) forces. Fractures produced by 
both types of bending are particularly common in long bones. Torsion 
loads are applied to a structure causing it to twist along an axis. 
Although each loading mode can be studied separately, bones in vivo 
are not only submitted to multiple different loads but also present 
irregular structure geometry112, 121. In vivo measurements of strain of 
a human adult tibia during walking demonstrated the complexity of 
the loading patterns during this common physiological activity. Stress 
values calculated from these strain measurements showed that 
during normal walking the stresses were compressive during heel 
strike, tensile during the stance phase and again compressive during 
push off. Moreover, the contraction of the muscles attached to the 
bone alters the stress distribution. During locomotion, bending 
moments are applied to the femoral neck and tensile stress is 
produced on the superior cortex. Contraction of the gluteus medius 
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muscle produces compressive stress that neutralizes this tensile 
stress112, 122-124. 
A progressive loss of bone density occurs as part of the normal aging 
process. The reduction of bone mass, which occurs earlier and more 
extensively in trabecular than in cortical areas74, is associated with 
impaired microarchitecture, increased fragility and risk of fracture. In 
osteoporotic bone, trabecular strength is reduced by loss of bone 
mass. Two different mechanisms were proposed to explain this 
phenomenon, a uniform thinning of all trabeculae and the complete 
removal of individual struts. Studies demonstrated that the random 
removal of struts is more harmful to bone strength than thinning of 
the trabeculae2, 125. Bone fragility is more prevalent among women 
than in men mainly because of estrogen deficiency after menopause. 
Although perforation and loss of connectivity between trabecula also 
occurs in men, trabecula thinning is primarily observed indicating that 
a reduction in bone formation predominates over an increase in bone 
resorption. Active remodeling also affects cortical bone. Cortical 
thinning and porosity reduce the resistance of bone to microcracks 
and, as a consequence, cortical bone can no longer absorb the energy 
imposed by a fall3, 74.  
Energy dissipation is achieved by the formation of plastic zones 
around the cracks, thereby protecting the integrity of the entire 
structure. At a nanoscale, deformation of individual collagen 
molecules involves hydrogen bonds which break allowing stretching 
and relaxation of the fibrils. At a higher scale we can find sliding and 
breaking of the bonds between tropocollagen molecules, which are 
critical in controlling deformation of bone. In fact, in older bones the 
collagen cross-links are increased, thereby reducing its ability to 
dissipate energy without failure. Continuous slide between the 
mineral particles and the tropocollagen molecules dissipates large 
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amounts of energy and increases the resistance to fracture126. The 
mineralized fibrils are hold together by phosphorilated proteins, such 
as OPN and BSP. During deformation, the non-collagenous proteins 
resist separation of the fibrils. This suggests that collagen 
denaturation induced by mechanical loading is a possible mechanism 
for energy dissipation process. Since more energy dissipation 
capacity gives more toughness to bone, enhancing the properties of 
collagen may make the bone tough127. 
 
 
BONE BIOLOGY 
Bone has three distinct cell types: the osteoclasts, or bone-resorbing 
cells; the osteoblasts, or bone-forming cells; and the osteocytes, 
which are osteoblasts entrapped within lacunae. Bone resorption and 
formation not only should be quantitatively balanced but must also be 
coupled in time and space. This tight coupling is essential for the 
repair of microscopic damages that result from constant impact128.  
In 1965, Frost described that groups of osteoclasts and osteoblasts 
constitute the bone multicellular unit (BMU)129 which is a mediator 
mechanism linking individual cell activity to whole bone 
morphology130. Nowadays, this concept has evolved to include 
osteocytes131. Inside the BMU, cells move together with osteoclasts 
always in the front of the advancing BMU and osteoblasts in the back. 
At any given time, several millions of BMUs carry out turnover at 
multiple skeletal sites in a activation-reversal-formation cycle that in 
a healthy adult human lasts 6-9 months132. In order to balance bone 
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formation and resorption in healthy individuals these two processes 
are coupled. That is to say that osteoblasts and its regulators 
determine osteoclastogenesis, while osteoclastogenesis and the 
products of the degraded matrix regulate osteoblastogenesis. In 
addition, both processes may be regulated by osteocytes and their 
products133-135. Resorption is much faster than formation: an area of 
bone can be resorbed in 2-3 weeks but it takes at least three months 
to rebuild it13. Bone resorption is probably the first event that occurs 
in response to a mechanical stress signal134. In fact, resorption and 
formation are tightly coupled, so that after resorption a formation 
phase occurs and, in normal bone, the amount of tissue resorbed will 
be rebuilt in the succeeding formation phase135.  
OSTEOCLAST 
The osteoclast is the unique bone-resorptive cell and is highly 
specialized towards this process. For its specific work, the osteoclast 
matures as a giant polykaryon through cell-cell fusion from its 
precursors136. The mammalian osteoclast contains up to eight nuclei 
with an in vitro diameter of 300µm, thus covering large areas to 
operate efficiently137. Net bone resorption is a reflection of both the 
number of osteoclasts and the degrading capacity of each individual 
cell138. Osteoclastogenesis is a complex process that includes many 
stages, such as commitment, differentiation, multinucleation and 
activation of immature osteoclasts139. 
The earliest identifiable hematopoietic precursor able to form 
osteoclasts is the granulocyte-macrophage colony forming unit (GM-
CFU)140. At this stage, the main transcription factors involved are 
spleen focus forming virus proviral integration oncogene spi1 (PU.1), 
microphthalmia-associated transcription factor (MITF) and FBJ murine 
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osteosarcoma viral oncogene homolog (FOS). PU.1 is responsible for 
the earliest events in osteoclastogenesis; PU.1 null mice lack not only 
osteoclasts but also macrophages, although they preserve the ability 
to form monocytes141. Moreover, the transcription of colony 
stimulating factor 1 receptor (C-FMS) gene, which encodes the 
receptor of colony stimulating factor 1 (macrophage) (M-CSF), is 
dependent on PU.1 and M-CSF and also plays a role in the earliest 
events of osteoclastogenesis by stimulating the proliferation and 
preventing apoptosis of early osteoclast precursors139. MITF has also 
been implicated in differentiation and survival of several cell types, 
including osteoclasts. Moreover, this transcription factor is expressed 
in macrophages, osteoclasts and in the mononuclear precursor of 
these cell types142. By interaction with PU.1, MITF regulates target 
genes such as the ones that encode CTSK, acid phosphatase 5, 
tartrate resistant (TRAP) and osteoclast associated, immunoglobulin-
like receptor (OSCAR), during osteoclast differentiation143. The 
protein FOS is a member of the transcription factor complex activator 
protein-1 (AP-1) and plays a role in early osteoclast differentiation as 
shown in animal model studies, where mice deficient in FOS develop 
osteopetrosis due to an osteoclast differentiation defect144. Moreover, 
FOS is a mediator of the lineage commitment between osteoclasts 
and dendritic cells (DC). The differentiation into an osteoclast or DC 
lineage is reciprocally inhibited by colony stimulating factor 2 
(granulocyte-macrophage) (GM-CSF) and M-CSF, respectively145. 
In 1988 it was established that the osteoclast precursor belongs to 
the monocyte/macrophage lineage146, as part of the cluster of 
differentiation (CD)14+CD16- monocyte subpopulation147. Moreover, it 
was demonstrated that osteoclasts could not be generated from bone 
marrow macrophages unless they were in contact with osteoblast-
lineage cells148. But it was only ten years later that receptor activator 
of nuclear factor kappa B (RANK) ligand (RANKL), a member of the 
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TNF superfamily, was found to be expressed on the surface of 
osteoblast-lineage cells and to be responsible for osteoclast 
differentiation149-150 through interaction with its receptor RANK at the 
surface of osteoclast precursors151. In a study using primary cultures 
of rat osteoclasts the authors settled that osteoprotegerin (OPG), a 
protein produced by osteoblasts, blocks RANKL and this effect was 
not only found on osteoclast precursors but also on mature 
osteoclasts152. Expression of RANKL and OPG regulates bone 
resorption by controlling the activation state of RANK on osteoclasts. 
The unique osteoclastogenic property of RANK is related to its ability 
to bind TNF receptor-associated factor (TRAF) 6, which stimulates 
mitogen-activated protein kinase (MAPK), phosphoinositide-3-kinase 
(PI3K) and nuclear factor kappa B (NFκB) pathways, as well as 
calcineurin153. Therefore, activation of RANK by its ligand leads to the 
expression of specific genes during differentiation, activation, 
participation in bone degradation and survival. At least five different 
intracellular cascades are induced during osteoclastogenesis and 
activation – inhibitor of NF-κB kinase (IKK), c-Jun N-teminal kinase 
(JNK), mitogen-activated protein kinase 14 (p38), extracellular 
signal-regulated kinase (ERK) and V-src sarcoma (Schmidt-Ruppin A-
2) viral oncogene homolog (SRC) pathways154. As members of the 
TNF receptor family lack intrinsic enzymatic activity, the key 
preliminary step of this signalling cascade is the binding of TRAFs to 
specific cytoplasmic domains of RANK155-156. There are multiple TRAFs 
that can bind to RANK157, however only TRAF6-deficient mice develop 
osteopetrosis due to impaired osteoclast function158. Therefore, 
TRAF6 acts as a key adaptor molecule of the signalling proteins that 
drive osteoclast-specific gene expression leading to cell differentiation 
and activation159. TRAF6 is not specific of RANK signalling but recent 
studies suggest that the quantitative difference in TRAF6-activation is 
probably the key mechanism that distinguishes RANK from other 
receptors regarding the osteoclastogenic potential160. NF-κB is one of 
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the earliest signals following RANKL stimulation and it is required for 
precursor survival during commitment to the osteoclast lineage, as 
well as for full differentiation161. The importance of the NF-κB 
pathway for osteoclast formation was demonstrated in mice deficient 
in p50 and p52 (two NF-κB subunits), that are osteopetrotic, due to 
defective osteoclast differentiation162. 
 
 
Figure 2 – Osteoclast lineage. 
Osteoclasts derive from hematopoietic precursors and proliferation of mononuclear 
cells requires M-CSF. When these cells arrive at the resorption site they fuse 
together in the presence of RANKL and M-CSF. These multinucleated precursors 
express osteoclast-specific genes and after polarization acquire the capacity to 
resorb bone.  
(αvβ3 - αvβ3 integrin; ATP6V0D2 - ATPase, H+ transporting, lysosomal 38kDa, V0 subunit 
d2; CALCR – calcitonin receptor; CLCN7 – chloride channel 7; CTSK – cathepsin K; DC-
STAMP - dendritic cell-specific transmembrane protein; FOS - FBJ murine osteosarcoma viral 
oncogene homolog; HSC – hematopoietic stem cell; M-CSF – colony stimulating factor 1 
(macrophage); MITF - microphthalmia-associated transcription factor; PU.1 – spleen focus 
forming virus proviral integration oncogene spi1; RANK - receptor activator of nuclear factor 
kappa B; RANKL – RANK ligand; TRAP - acid phosphatase 5, tartrate resistant) 
 
In addition to RANKL, M-CSF is another essential cytokine to generate 
osteoclasts, as it promotes precursors proliferation and survival. This 
cytokine is produced by several cells, but cells from the osteoblast 
lineage are the major source during osteoclastogenesis163. Mice 
deficient in M-CSF (op/op mouse) are characterized by osteoclast-
deficient osteopetrosis164. Together, M-CSF and RANKL are required 
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to induce expression of osteoclast lineage-specific genes (figure 2), 
including those encoding TRAP, CTSK, calcitonin receptor (CALCR) 
and αvβ3 integrin, leading to the development of mature 
osteoclasts165. 
Osteoclast precursors differentiate into TRAP+ mononuclear cells after 
RANKL stimulation. These cells fuse with each other and differentiate 
into multinucleated osteoclasts166. Cell fusion is one of the most 
distinctive characteristic properties of osteoclasts. An osteoclast 
precursor cell in contact with a RANKL presenting cell will receive the 
RANKL signal to initiate a cascade of gene expression that includes 
the production of the chemokines monocyte chemotactic protein-1 
(MCP-1) and regulated upon activation normal T cell expressed and 
secreted (RANTES) which are chemotactic signals for monocytes167. 
Osteoclast cell fusion occurs within RANK+ mononuclear precursors in 
2D directions and the major effect of multinucleation is the increase 
in cell size, creating multinucleated giant osteoclasts that resorb 
larger areas of bone tissue136. RANKL, via nuclear factor of activated 
T-cells, cytoplasmic, calcineurin-dependent 1 (NFATc1), induces the 
expression of two proteins dendritic cell-specific transmembrane 
protein (DC-STAMP) and ATPase, H+ transporting, lysosomal 38kDa, 
V0 subunit d2 (ATP6V0D2) required for osteoclast multinucleation168-
169. In DC-STAMP-deficient mice, osteoclast cell fusion is impaired 
despite normal expression of osteoclasts markers170 and in another 
study this molecule was up-regulated following stimulation with 
RANKL171-172. The osteoclastic ability of DC-STAMP-/- mononuclear 
cells is impaired but not completely blocked; therefore, DC-STAMP is 
important for cell fusion but not essential for bone resorption activity. 
Moreover, inactivation of ATP6V0D2, an isoform of the osteoclast H+ 
ATPase transporter, lead to resorptive dysfunction in mice by lack of 
efficient pre-osteoclast fusion173. The DC-STAMP-expressing 
osteoclast becomes the master-fusing cell and fuses with a DC-
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STAMP-negative follower cell. Once fusion of the two cells is 
completed, a binucleated cell is formed and this cell becomes the 
master fuser and can fuse with other mono or multinucleated cells174. 
Overall, cell-cell fusion is a tightly regulated process involving several 
steps. Cells have to acquire the capacity to fuse and then, fusion-
competent cells have to move towards each other, attach and bring 
their membranes in close contact. Finally, the cell membranes must 
be merged and the resultant multinucleated cell has to reorganize 
cellular components in order to become functional175. 
The mature osteoclast is rich in mitochondria to produce energy for 
the resorption process and is a polarized cell with the nuclei localized 
towards the resorptive surface. The osteoclast also contains a unique 
and complex ruffled membrane, which is the resorptive organelle. 
Although the origin of this specialized membrane was enigmatic for 
some time, it is now considered to be the most specific marker of the 
osteoclast since it appears only when the cell is resorbing bone138. 
Recent findings point to a lysossomal origin of this organelle. In fact, 
synaptotagmin VII, a calcium sensor protein that regulated 
exocytosis, is associated with lysosomes in osteoclasts and the 
absence of this protein inhibits CTSK secretion and formation of the 
ruffled border but without interfering with cell differentiation176. The 
ruffled border is formed upon contact of the cell with the bone surface 
by transport of acidified cytoplasmic vesicles to this area. This 
organelle is surrounded by an actin-rich structure known as actin ring 
or sealing zone which creates an isolated microenvironment where 
organic and inorganic components of bone are degraded163. The 
primary component of the osteoclast cytoskeleton is F-actin and this 
cell has a distinct actin complex known as podosome which mediates 
its attachment to bone177. The osteoclast attaches to bone surface via 
αvβ3 integrin binding to the Arg-Gly-Asp (RGD) residues, a 
component of matrix proteins such as OPN and BSP. Upregulation of 
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αvβ3 expression is characteristic of monocytes as they become 
osteoclasts and it is an important molecule in cell motility, adhesion 
to bone matrix and polarization. Osteoclasts of β3-/- mice are not able 
to form actin rings and have attenuated ruffled membranes leading to 
diminished resorptive activity and increased bone mass178. In the 
osteoclast, αvβ3 is maintained in a basal low-affinity state by 
interactions between the α and β subunits; during bone resorption the 
activated conformation is prevalent in the ruffled membrane whereas 
the basal form is present in the sealing zone. This conformation shift 
is modulated by M-CSF and integrin activation is necessary for the 
binding to RGD motifs present on bone matrix, leading to osteclast 
attachment to bone179. The cytoskeleton structure is controlled by 
interaction between αvβ3 integrin and the M-CSF pathway. M-CSF 
binds to its receptor C-FMS and activates the integrin by targeting its 
cytoplasmic domain and changing the conformation of its extracellular 
ligand-binding region180. Consequently, osteoclasts stimulated with 
M-CSF undergo cytoskeletal reorganization, acquiring a motile 
phenotype mediated by the activation of Vav3/Rac pathway181. Bone 
resorption is a cyclic process in which the cell migrates to a resorptive 
site, degrades the underlying matrix, detaches and re-initiates the 
cycle. Optimal bone resorption depends upon these cycles and the 
αvβ3 integrin is critical for all phases182. 
The osteoclast ability to resorb bone depends on the capacity of 
cytoskeletal organization to create an intimate microenvironment with 
bone surface. Observation of the pits formed by osteoclasts 
demonstrates that each cell typically produces a path that is longer 
than the cell width, indicating that migration is part of the resorption 
process. As the cell moves, it rearranges its cytoskeleton to form new 
sealing zones and dissolve old ones; in fact a single resorbing 
osteoclast can form several sealing zones168. Inside this specific 
microenvironment the key events that lead to bone degradation 
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occur. The first study about the basic mechanism of bone degradation 
was performed in 1985 and established that the resorptive space is a 
highly acidified microenvironment183. The acidification process is 
initiated by a carbonic anhydrase184 and the protons generated are 
transported to the resorptive lacunae via an ATP-dependent proton 
pump185. Concomitantly, intracellular pH is maintained by an energy-
independent Cl-/HCO3- exchanger on the cell anti-resorptive 
surface186 and Cl- ions are transported to the resorptive lacunae 
through chloride channel (CLCN) 7187. Therefore, acidification of the 
extracellular microenvironment represents production of hydrogen 
chloride (HCl) within this confined space. The low pH maintained in 
the resorptive lacunae is necessary and sufficient to dissolve the 
mineral phase of the matrix, which is followed by degradation of bone 
organic matrix163. The HCl dissolves the solid hydroxyapatite 
[Ca3(PO4)2]3Ca(OH)2 to Ca2+, HPO4- and H2O137. Bone collagen 
degradation occurs through the action of a lysosomal enzyme, CTSK, 
which also polarizes to the ruffled membrane upon osteoclast 
attachment to bone188.  
Overall, the process of bone resorption can be divided into four steps. 
First, the mononuclear precursors fuse to form a polykaryon and 
target to the site of resorption. They will then attach to bone surface 
stimulating the reorganization of the actin cytoskeleton and forming 
the actin ring and the sealing zone. In the third step the ruffled 
border is created. Finally, the resorption lacunae will be acidified and 
proteases will be secreted into this space, resulting in mineral 
dissolution and organic matrix degradation. After resorption, the 
osteoclast will detach from the matrix, lose its polarization and either 
relocate to a new resorption site or undergo apoptosis137. 
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OSTEOBLAST 
Osteogenesis is a highly regulated process involving the 
differentiation of mesenchymal stem cells (MSC) into osteoblasts, 
which produce a characteristic extracellular collagenous matrix where 
hydroxyapatite crystals deposit. Osteoblasts can exhibit two opposite 
phenotypes. One is the osteogenic phenotype, which characterizes 
cells that secrete bone matrix at the bone resorption site, while the 
osteoclastogenic phenotype, supports osteoclast differentiation in old 
bone areas. 
Osteoblasts are mononuclear, not terminally differentiated, 
specialized cells189. As they differentiate they acquire the ability to 
secrete bone matrix190. Osteoblasts resemble fibroblasts. In fact, the 
only morphological specific trait is located outside the cell in the form 
of a mineralized extracellular matrix. Moreover, all the genes 
expressed by fibroblasts are also expressed by osteoblasts. In fact, 
these cells have only two specific transcripts, one encoding RUNX2 
and other encoding OCL191.  
Osteoblasts, chondrocytes, adipocytes, myoblasts, tendon cells and 
fibroblasts are all derived from MSC (figure 3). The lineages are 
determined by specific transcription factors192. RUNX2, osterix (OSX) 
and β-catenin are three factors necessary and sufficient to the 
differentiation of a MSC into an osteoblast193. RUNX2 directs 
mesenchymal progenitor cells to preosteoblasts, inhibiting their 
differentiation into adipocytes and chondrocytes, while OSX and β-
catenin further direct the preosteoblasts to immature osteoblasts, 
completely eliminating the potential for differentiating into 
chondrocytes192. 
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Figure 3 - Mesenchymal precursors differentiate into several lineage cells. 
Mesenchymal stem cells give rise to several cell types depending on the 
transcription factors expressed. PPARγ and C/EBPα are required for adipocyte 
differentiation, while RUNX2, CTNNB1 and OSX are necessary for both osteoblast 
formation and chondrogenesis require SOX9.  
(C/EBPα – CCAAT/enhancer-binding protein α; CTNNB1 - β-catenin; MSC – mesenchymal 
stem cell; OSX – osterix; PPARγ - peroxisome proliferator-activated receptor γ; RUNX2 – 
runt-related transcription factor 2; SOX9 - SRY (sex determining region Y)-box 9) 
 
The progressive development of the osteoblast phenotype from a 
proliferating immature cell to a mature osteoblast that is able to 
synthesize bone proteins is characterized by a sequential expression 
of specific genes that identifies three periods of osteoblast phenotype 
development: proliferation, maturation and extracellular matrix 
synthesis, and matrix mineralization (figure 4)194. It is hypothesized 
that osteoblast proliferation is dependent on the matrix synthesis, 
whose maturation contributes to up-regulate the proliferation stage. 
During the active proliferation phase, osteoblast-committed 
progenitor cells express genes that support proliferation and several 
genes encoding for extracellular matrix proteins, such as type I 
collagen. These precursor cells are elliptical and unable to deposit 
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bone matrix, but retain the proliferation capacity. At this point, BMP-2 
and BMP-5 have a key role in increasing alkaline phosphatase (ALP) 
activity and OCL synthesis194-195. Immediately after growth arrest, a 
development sequence of specific genes that characterize osteoblasts 
(ALP, OCL) occurs. The accumulation of matrix proteins leads to the 
suppression of cell proliferation196.  
 
 
 
Figure 4 – Osteoblast lineage. 
Osteoblasts derive from mesenchymal stem cells and differentiate only in the 
presence of DLX5, RUNX2, OSX and CTNNB1. The pre-osteoblast is unable to 
deposit bone matrix but maintains the proliferation capacity. Moreover, the amount 
of RANKL and OPG expressed by osteoblasts depend on their stage of 
differentiation: pre-osteoblast cells express high levels of RANKL and relatively low 
levels of OPG, thus stimulating osteoclast differentiation and function. Immediately 
after growth arrest, a development sequence of specific genes that characterize 
osteoblasts occurs.  
(ALP – Alkaline phosphatase; BSP – bone sialoprotein; COLI – type I collagen; CTNNB1 - β-
catenin; DLX5 - distal-less homeobox 5; MSC – mesenchymal stem cell; OPG – 
osteoprotegerin; OPN – osteopontin; OSX – osterix; RANKL - receptor activator of nuclear 
factor kappa B ligand; RUNX2 - runt-related transcription factor 2) 
 
The active osteoblast is a cuboidal cell with an abundant rough 
endoplasmic reticulum and a large Golgi apparatus. In addition, 
osteoblasts form tight junctions with adjacent osteoblasts and have 
plasma membrane regions specialized in vesicular trafficking and 
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secretion that facilitate the deposition of bone matrix64, 197. During the 
post-proliferative phase, which is characterized by high levels of ALP, 
the extracellular matrix progresses to the mineralization phase, in 
which osteoblasts synthesize several proteins associated with the 
mineralized matrix198 including BSP199, OPN and OCL200. OPN is 
expressed during active osteoblast proliferation, decreases 
immediately after the post-proliferative stage and increases again at 
the onset of mineralization, achieving a peak during mineralization201. 
On the other hand, OCL is expressed only in the post-proliferative 
phase, showing highest levels during mineralization202. At the end of 
the matrix synthesis and mineralization, expression of ALP 
diminishes201 and osteoblasts either undergo apoptosis, become lining 
cells or maturate into osteocytes194.  
More than a decade ago, RUNX2 was established as essential for bone 
formation since mice deficient in this transcription factor showed no 
ossification203. RUNX2 is a member of the runt family of transcription 
factors that is expressed by MSCs at the onset of skeletal 
development and is present in osteoblasts throughout their 
differentiation204. Mice overexpressing RUNX2 exhibit osteopenia and 
multiple fractures, as a consequence of the reduced number of 
terminally differentiated osteoblasts and diminished number of 
osteocytes, whereas less mature osteoblasts expressing OPN 
accumulated in adult bone. Therefore, although essential for 
osteoblast lineage commitment and proliferation, RUNX2 inhibits 
differentiation at a later stage205. In bone lineage cells, RUNX2 binds 
to the osteoblast specific element (OSE2), that is found in the 
promoter region of all major osteoblast genes and controls their 
expression206, including type I collagen α1 chain (COL1A1)207, OPN208, 
BSP209 and OCL207. 
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Osterix is another essential transcription factor for osteoblast 
differentiation. OSX-deficient mice show absence of osteoblasts and 
defective bone formation210; however, RUNX2 is expressed in these 
mice suggesting that OSX acts downstream of RUNX2. In fact, OSX 
transcription is positively controlled by RUNX2211. OSX acts by 
forming a complex with NFATc1 resulting both in the activation of the 
type I collagen promoter212 and in the induction of WNT signaling 
pathway and bone formation213. 
The WNT signaling pathway regulates several aspects of osteoblast 
activities including commitment of mesenchymal stem cells, 
osteoblast progenitor amplification and cell death. The first evidence 
that WNT/β-catenin signalling plays an important role in bone 
formation came from studies in humans where mutations that 
inactivate the WNT co-receptor low density lipoprotein receptor-
related protein (LRP)5 were shown to cause osteoporosis214. 
Moreover, gain-of-function mutations in this receptor increased WNT 
signalling and resulted in a high bone mass phenotype, both in 
humans and mice, due to an elevated number of active osteoblasts 
which seem to be protected from apoptosis215. 
WNTs are secreted glycoproteins that are found in all animal species. 
The human genome encodes 19 WNT genes that bind to cell-surface 
receptors and mediate a cascade of events that regulate a variety of 
cellular activities, including cell fate, determination, proliferation, 
migration, polarity and gene expression. The WNT/β-catenin pathway 
(figure 5) is frequently referred to as the canonical pathway and it 
promotes cell fate determination, proliferation and survival through 
the increase of β-catenin levels and alteration of gene expression by 
the transcription factor lymphoid enhancer factor/T cell factor 
(LEF/TCF)216. Activation of this signalling pathway occurs with binding 
of WNT to the receptor Frizzled (FZ) and the co-receptors LRP5/6217-
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218. In the absence of a WNT ligand, the cytosolic level of β-catenin is 
kept low by its phosphorylation and degradation, thereby suppressing 
the expression of WNT-responsive genes216. 
 
 
 
Figure 5 - Wnt/β-catenin signaling pathway. 
Canonical Wnt signalling has multiple roles in osteoblastogenesis, is essential for 
osteoblast lineage differentiation and is involved in osteoblast proliferation, survival 
and lifespan. Binding of WNT to FZ and LRP5/6 receptors induce a signalling 
cascade that allows the accumulation of β-catenin in the cytoplasm. β-catenin then 
enters the nucleus where it promotes the transcription of target genes.  
(APC – adenomatous polyposis coli; β-cat - β-catenin; DKK-1 – dickkopf-related protein 1; 
DVL – dishvelled; FZ – frizzled receptor; GSK3 – glycogen synthase kinase-3β;  LRP5/6 - 
low-density lipoprotein receptor related protein 5/6; sFRP – secreted frizzled-related protein; 
SOST – sclerostin; WIF-1 – WNT inhibitory factor; LEF/TCF – lymphoid enhancer factor/T cell 
factor) 
 
β-catenin activity is essential for the differentiation of mature 
osteoblasts and, consequently, for bone formation. In fact, 
conditional inactivation of β-catenin in either skeletal progenitor cells 
or at a later stage of osteoblast development in mouse embryos 
blocks osteoblast differentiation219. LRP5 is expressed at low levels in 
various tissues and constitutes a key factor in bone regulation. This 
39 
 
factor forms a complex with FZ, leading to the activation of the 
canonical WNT signalling pathway217-218, 220. Moreover, recent studies 
have shown that OSX is able to inhibit WNT pathway activity during 
osteoblast differentiation either through disrupting the biding of TCF 
to DNA and inhibiting β-catenin transcription, or by activating the 
dickkopf homolog 1 (DKK1) promoter, an endogenous inhibitor of the 
WNT/β-catenin signaling221-222. Although this pathway has been 
extensively studied on osteoblastogenesis and bone formation, 
specific WNT proteins able to trigger its activation have still not been 
identified. In fact, several WNT genes, such as WNT1, WNT4, WNT5α, 
WNT9α/14 and WNT7b are expressed in either osteoblast precursors 
or adjacent tissues during development, and WNT3α and WNT10b are 
expressed in bone marrow217, but only WNT10b mutants show a 
postnatal decrease in bone mass. WNT10b induces the expression of 
the transcription factors RUNX2223-224, distal-less homeobox 5 (DLX5) 
and OSX225 in mesenchymal progenitor cells in vitro. Additionally 
WNT10b blocks adipogenesis by inhibiting the transcription factors 
CCAAT/enhancer-binding protein α (C/EBPα) and peroxisome 
proliferator-activated receptor (PPAR)γ223. These observations 
substantiate the influence of WNT/β-catenin pathway on the 
differentiation of the mesenchymal stem cells towards an osteoblastic 
phenotype both by inhibiting adipogenesis and inducing osteoblast-
specific transcription factors. LRP5/6 appears to regulate the number 
of osteoblasts and their proliferation226 while β-catenin influences OPG 
production in osteoblasts and affects bone resorption but without 
having impact on their number227. Moreover, WNT/β-catenin 
signalling activation enhance osteoblast and osteocyte survival in 
vitro219 and this pathway is also active during bone regeneration228.  
WNT signalling is tightly regulated by secreted antagonists. There are 
two classes of WNT inhibitors, the secreted frizzled-related protein 
(sFRP) class and the dickkopf class. Members of the sFRP class bind 
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directly to WNTs and members of the dickkopf class, which comprise 
some dickkopf family of proteins and sclerostin (SOST), inhibit WNT 
signalling by binding to the LRP5/6 co-receptor229-230. The dickkopf 
family of proteins comprises four members. DKK1, the most studied 
one, is a secreted protein whose function is to prevent the activation 
of the WNT signalling pathway by binding to LRP5/6231. DKK1 inhibits 
the WNT pathway through interaction with another transmembrane 
receptor, Kremen (KRM)-1 and KRM-2, forming a ternary complex 
(DKK1-KRM-LRP5/6) and disrupting the signalling by promoting 
endocytosis and removal of the WNT receptor from the cell 
membrane232. Transgenic mice overexpressing DKK1 have reduced 
osteoblast numbers and severe osteopenia233, whereas deletion of 
only one DKK1 allele increases all bone formation parameters without 
affecting bone resorption234. Single KRM mutants show normal bone 
formation while double mutants show increased bone mass 
parameters, both without interfering with bone resorption markers235. 
Canonical WNTs upregulate DKK2 expression which, in turn, controls 
some of the processes required for terminal osteoblast differentiation, 
mostly by removing the cells from the cell cycle. This protein is 
important in late stages of osteogenic differentiation, particularly for 
the formation of mineralized matrix. In fact, DKK2-/- mice are 
osteopenic, have increased numbers of osteoclasts and show elevated 
levels of RANKL; therefore, DKK2 seems to influence both osteoblast 
and osteoclast biology236. 
Sclerostin is a secreted protein expressed by mature osteocytes237 
and its expression is modulated by mechanical loading238. Like DKK1, 
SOST inhibits WNT/β-catenin pathway by binding to LRP5/6 co-
receptor; however, it binds to a different region of LRP5/6 and it does 
not mediate receptor internalization239. SOST knockout mice have 
increased BMD, bone volume, bone formation and bone strength240 
while overexpression of SOST leads to osteopenia241. Mutations that 
41 
 
reduce SOST function, in humans, cause sclerosteosis characterized 
by endosteal hyperostosis, most commonly of the skull and mandible 
242. 
BMPs, namely BMP-2, BMP-4 and BMP-7, are able to induce immature 
cells to differentiate into osteoblasts243. Specifically, BMP-7 induces 
the expression of RUNX2 indicating that this gene is a target of BMP 
signalling during osteoblast differentiation244. 
Osteoblasts have the ability to regulate bone resorption through the 
expression of RANKL, which binds to its receptor, RANK, on the 
surface of pre-osteoclast cells, inducing their differentiation. On the 
contrary, the soluble decoy receptor OPG, also produced by the 
osteoblast, is able to block RANK/RANKL interaction by binding to 
RANKL and thus prevent osteoclast differentiation and activation245. 
RANKL was initially identified as a cytokine produced by T cells and 
needed for their interaction with DCs246. RANKL is expressed by 
osteoblasts, bone marrow stromal cells, activated immune system 
cells246-247, mammary epithelial cells248, cells within the periodontal 
tissue249, hypertrophic chondrocytes149 and smooth muscle cells250. 
Evidence has shown that RANKL exists in two forms; a 40 to 45kDa 
membrane-bound form and a 31KDa soluble form149, 251. In vitro 
studies confirmed that the soluble form can be generated by 
proteolytic cleavage of the membrane-bound form by proteinases 
such as TNF-α converting enzyme (TACE)252, a disintegrin and MMP 
(ADAM) 10 and MMP14253. In addition to proteolytic cleavage, in 
malignant cells a human soluble form of RANKL can be produced by 
alternative splicing254-255. However, some data suggest that the 
membrane-bound form is more potent than the soluble one256 since 
shedding of RANKL from stromal cells inhibits osteoclastogenesis in 
vitro and mice with reduced RANKL shedding have increased 
osteoclast number253. Moreover, shedding of RANKL is suppressed 
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either by binding of OPG or soluble RANK to RANKL257 and transgenic 
mice overexpressing soluble RANKL are osteoporotic258.  
TNF family members mediate several biological processes and RANKL 
is especially important in bone, in the immune system259 and in 
mammary epithelium245. Deletion of the RANKL gene in mice resulted 
in severe osteopetrosis and a complete lack of osteoclasts, as a result 
of an inability of osteoblasts to support osteoclastogenesis260. OPG 
was first identified in 1997 as being a protein that exhibits a 
protective effect on bone261, although it is expressed ubiquitously and 
abundantly in many tissues and cell types262. OPG was identified only 
as a soluble protein261, 263 which binds to its ligand, thereby 
preventing the activation of cellular targets. In fact, the main function 
of OPG is to antagonize RANKL effects, by interrupting the signalling 
between osteoblasts and osteoclast progenitors. Indeed, 
overexpression of OPG in mice also resulted in osteopetrosis due to 
inhibition of osteoclast maturation261, whereas OPG-deficient mice 
exhibit osteoporosis264. In an in vitro study, RANKL mRNA levels were 
found to be increased in undifferentiated cells and decrease 5-fold 
during osteoblast differentiation, whereas OPG mRNA levels were 
much lower in undifferentiated cells and increased 7-fold during 
differentiation265-266. These findings are in agreement with the fact 
that only undifferentiated cells can support osteoclastogenesis, while 
partially or completely differentiated cells cannot. Accordingly, the 
amount of RANKL and OPG expressed by osteoblasts depend on their 
stage of differentiation: pre-osteoblast cells express high levels of 
RANKL and relatively low levels of OPG, thus stimulating osteoclast 
differentiation and function (figure 4). On the other hand, more 
mature osteoblasts express higher levels of OPG, in comparison to 
RANKL levels, inhibiting osteoclast differentiation and function190. 
Hence, a high RANKL/OPG ratio in bone microenvironment is the 
main molecular mechanism that determines osteoclastogenesis. 
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Following lineage commitment, osteoprogenitors undergo a 
proliferative stage. Subsequently, they exit cell cycling and begin to 
express genes encoding several proteins such as ALP, BSP and type I 
collagen as they start to produce and mature the extracellular matrix. 
Finally, osteoprogenitors express genes of proteins involved in the 
mineralization of the extracellular matrix such as OCL and OPN267.  
 
OSTEOCYTE 
At the end of the bone formation phase osteoblasts have one of three 
possible fates: they can be embedded in the matrix and differentiate 
into osteocytes, they can be transformed to bone lining cells or they 
can undergo programmed cell death268. Thus, an osteocyte is an old 
osteoblast that was entrapped in its own matrix. It remains unclear if 
the decision for an osteoblast to become an osteocyte is determined 
by a specific pattern of gene expression, weather it is a cell 
autonomous response or one that is controlled by signals received by 
the surface cells from already embedded osteocytes. It is also not 
known whether every osteoblast can become an osteocyte or if there 
is a specific subpopulation with predefined fate269. Several 
investigators have reported heterogeneity in osteoblast gene and 
protein expression patterns, suggesting the existence of 
subpopulations of osteoblasts destined for different fates270-271.  
Osteocytes are non-proliferative, terminally differentiated cells and 
constitute the main cellular component of mammalian bone, 
representing more than 95% of bone cells. They reside both in 
mineralized matrix and in newly formed osteoid, locked inside small 
lacunae. Osteocytes have dendritic morphology. The cells are located 
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in osteocytic lacunae and present cytoplasmic extensions, dendrites, 
which extend into channels in the matrix, called canaliculi. Although 
they are considered non-migratory, osteocytes are motile within the 
lacuno-canalicular system and they are able to retract and extend 
their cytoplasmic processes in the canals272. Osteocytes communicate 
with each other and with cells at bone surface via these dendrites and 
the lacuno-canalicular system constitutes a molecular exchange 
surface area273. Once embedded into the bone matrix, the osteocyte 
ceases its matrix synthetic activity and initiates the function as strain 
and stress sensor274. Another function of osteocytes within the bone 
cell network is the ability to deposit and resorb bone around the 
lacuna in which they are housed, thus changing the shape of the 
lacuna. This process is called osteocytic osteolysis and is limited to 
specific situations275. In an attempt to understand if the osteocyte 
can be released from its lacunae, it was found that when bone around 
embedded osteocytes is resorbed, osteocytes either appear to 
undergo cell death or they crawl out of the lacunae into the resorbed 
area269. However, the faith of the free cell is unknown. 
During osteocytogenesis the embedding cell undergoes a dramatic 
transformation. In order for osteoblasts to differentiate into 
osteocytes they first need to arrest their motion on bone surface and 
adopt a dendritic morphology. At this phase, the organized 
expression of tubulin, vimentin and actin in cell bodies and dendrites 
of osteocytes are crucial to maintain their characteristic cytoskeletal 
shape276. Many researchers believe that the transformation process 
involves three cell types: preosteoblasts differentiate into osteoblasts 
which become trapped as osteocytes. During the transformation 
process there is a wide range of morphological changes such as 
decrease in size of the cell body (about 70% reduction in body 
volume), increase in the cellular processes and changes in 
intracellular organelles. In the nascent osteocyte, the structure of 
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organelles is qualitatively similar to that of osteoblasts, although the 
size and number are diminished. In fact, with increasing distance 
from the mineralizing surface the rough endoplasmic reticulum, the 
Golgi apparatus and mitochondria decreases and glycogen 
accumulation increases277-278. During bone formation, processes of 
the osteocyte surface continue to grow to enable this cell to maintain 
contact with the active osteoblast layer and modulate their activity. 
When these processes stop growing they produce a signal that 
induces recruitment of those osteoblasts with which they are losing 
contact. The committed osteoblasts start differentiating into 
osteoblastic osteocytes279. Studies in the femoral metaphysis of 2-
week old rabbits suggest that the transformation from osteoblast to 
osteocytes takes about three days280. During this time, the cell 
produces a volume of extracellular matrix three times its own cellular 
volume278. The osteoid osteocyte must perform two major functions 
simultaneously: regulate mineralization and form connective dendritic 
processes281-282.  
Osteocyte differentiation (figure 6) is accompanied by progressive 
reduction of several bone markers such as ALP, BSP, OCL, collagen 
type I and RUNX2. The expression of OPN and podoplanin (E11/gp38) 
is maintained. On the other hand, osteocytes start expressing new 
markers like CD44, dentin matrix acidic phosphoprotein 1 (DMP1) and 
matrix extracellular phosphoglycoprotein (MEPE)274, 283. After 
mineralization of the osteoid, the osteocyte undergoes morphological 
changes that lead to a decrease in protein synthesis. Although the 
molecular control of osteocytogenesis is largely unknown, this 
process is accompanied by increased expression of MEPE and DMP1, 
which have been associated with the osteocyte phenotype284-285. 
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Figure 6 – Osteocytogenesis. 
Osteocytes derive from matrix-secreting osteoblasts. By an unknown mechanism, 
osteocytes become entrapped in the bone matrix while maintaining contact with 
each other and with cells at the bone surface through cytoplasmic projections. 
During entrapment, the cell morphology changes until it acquires the typical 
morphology with a small cell body and numerous dendritic processes.  
(ALP – Alkaline phosphatase; COLI – type I collagen; DMP1 - dentin matrix acidic 
phosphoprotein 1; E11/GP38 – podoplanin;  FGF23 – fibroblast-growth factor 23; MEPE - 
matrix extracellular phosphoglycoprotein; OCL – osteocalcin; OPG – osteoprotegerin; PHEX - 
phosphate regulating endopeptidase homolog, X-linked; RANKL - receptor activator of 
nuclear factor kappa B ligand; SOST – sclerostin) 
 
DMP1 is an extracellular matrix protein that has been implicated in 
osteocyte function and signaling286. DMP1 is a target for RUNX2 and 
is absent in RUNX2 knockout animals. In a DMP1 knockout model a 
hypomineralized phenotype is present and associated with elevated 
fibroblast growth factor (FGF)23 and defective lacuno-canalicular 
network formation287. Moreover E11/gp38 is highly expressed in 
osteocytes that are in the process of embedding or have recently 
been embedded, suggesting that this molecule may be important for 
the initial formation of dendrites but not for the subsequent 
maintenance of their morphology. In vitro studies suggest a link 
between this molecule and the dendritic nature of osteocytes since 
overexpression of E11/gp38 in osteoblasts initiates the development 
of cytoplasmic processes, while blockade inhibits them288. MMP-2 has 
also a role in osteocytogenesis. Recent work describes MMP-2 as a 
regulator of osteocyte production, generation and maintenance of an 
appropriate canalicular system, since in MMP-2 knockout mice the 
number of canaliculi is reduced289. Although osteocytes by 
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themselves do not resorb or form bone, except in the lacunar area, 
they signal osteoblasts and osteoclasts to perform their functions. 
Osteocytes have been shown to produce RANKL and M-CSF and to 
support the generation of functional resorbing osteoclasts from their 
progenitors290-291. These cells also express OPG, influenced by β-
catenin signaling172, 282. Mechanical pressures and loads are sensed 
by osteocytes and these cells are able to respond by modulating the 
expression and secretion of many molecules, including IGF-I, IGF-II, 
OCL292 and type I collagen293. Osteocytes also produce two important 
inhibitors of osteoblast proliferation and differentiation SOST241 and 
DKK1233. 
Osteocytes not only play a physiological role during their lifetime but 
also achieve functions through apoptosis. It has been observed that 
pro-apoptotic molecules are elevated in osteocytes found in the 
vicinity of microcracks, whereas anti-apoptotic molecules are 
expressed 1-2mm from the microcrack, suggesting that the apoptotic 
area may be restricted to the neighborhood of the damage294. The 
osteocyte apoptosis message travels through the lacuno-canalicular 
system to the bone surface and is sensed by the progenitor cells. This 
message leads to the initiation signals for remodeling, stimulating the 
bone resorption/formation cycle295.  
 
THE REMODELING PROCESS 
Bone is continuously remodelled to ensure mineral homeostasis and 
to maintain the integrity and strength of the structure. Bone 
remodeling occurs at the BMU level and involves several sequential 
steps beginning with osteoclast formation, osteoclast-mediated bone 
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resorption, a reversal period where the matrix will be prepared for 
the next phase and a long period of bone matrix formation mediated 
by osteoblasts, followed by mineralization of the matrix (figure 7)296-
297. In this process cells are not in contact with bone marrow but are 
enclosed in a specialized vascular structure that Hauge called bone 
remodeling compartment (BRC). This compartment is covered by a 
canopy of cells that form the outer delineation that display the classic 
osteoblast lineage markers and, therefore, are most probably lining 
cells298. These cells communicate with each other and with osteocytes 
embedded in bone matrix via gap junctions. Capillaries infiltrate the 
canopy probably serving as a transportation system for the cells 
needed in the BMU. In fact, cells may enter the remodeling space 
either via diapedesis through lining cells or capillaries131, since there 
are evidence that both osteoclast146 and osteoblast299 precursor cells 
are present in the circulation.  
Essentially, BRC provides a closed microenvironment suitable for the 
tight regulation necessary for bone resorption-formation coupling and 
allows remodeling to proceed without interference from local factors 
liberated in the bone marrow. The BRC is the structure that translates 
microdamage sensed by the osteocyte network into osteoclast and 
osteoblast activity. Signals sensed by osteocytes are transmitted to 
the lining cells layer300-301 and trigger osteoclast precursor 
recruitment. Coupling occurs inside the BMU; however, due to the 
separation in time and space of bone resorption and formation, the 
cell-cell contact between osteoclast precursors and active osteoblasts 
is highly unlikely131. Therefore it was proposed that lining cells, which 
express OPG and RANKL302, might be responsible for cell-cell contact 
with osteoclast precursors. Bone surface is generally covered by 
lining cells277 preventing direct contact between osteoblasts or 
osteoclasts and integrins or other adhesion molecules present on 
bone surface. Due to the fact that BRC formation involves 
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detachment of lining cells from bone surface, BRC would be the only 
place where circulating osteoblasts and osteoclasts precursors are 
exposed to matrix constituents. Therefore, this structure eliminates 
the need of a “postal code” system to ensure that cells migrate and 
adhere to the areas where they are needed131. 
 
 
Figure 7 – The remodeling process. 
The remodeling process takes place inside the bone remodeling compartment. Bone 
remodeling is hypothesized to be initiated by osteocyte apoptosis (activation 
phase), which sends a signal for the recruitment of osteclast precursors, which then 
differentiates and resorb bone in this closed microenvironment (resorption phase). 
Following osteoclast-mediated resorption, the lacunae remains covered with 
undigested demineralised collagen matrix and will be cleaned by osteal 
macrophages (reversal phase). At last, osteoblasts arrive at the bone remodeling 
compartment where they will deposit new bone (formation phase).  
 
The trigger that initiates bone remodeling is thought to be osteocyte 
apoptosis303. Studies of mechanical loading in human bone ex vivo 
and of rat bone in vivo determined that osteocyte apoptosis is 
increased by loading and was accompanied by increased 
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remodeling304-305. Under normal conditions, osteocytes secrete TGFβ, 
inhibiting osteoclastogenesis. When these cells undergo apoptosis, 
TGFβ levels diminishes, removing the osteoclastogenesis inhibitory 
signal and allowing osteoclast formation306. Moreover, osteocytes are 
able to secrete OPG and M-CSF and express RANKL, which enables 
them to control osteoclastogenesis291, 307.  
Osteoblasts respond to the stimuli generated by osteocytes and 
recruit osteoclast precursors to the remodeling site. During 
recruitment, osteoclast precursors migrate from the bloodstream into 
the extravascular space, through the endothelial cell layer. Studies 
have shown that two routes for this journey can be considered: either 
the precursors migrate via cell-cell junctions (paracellular 
migration)308 or through the cell body of endothelial cells 
(transcellular migration)166, 309. At this time, osteoblast decrease the 
expression of OPG and enhance M-CSF and RANKL production in 
order to promote osteoclast differentiation and activity. Osteoblasts 
also produce MMPs in response to the remodeling signal310. These 
enzymes expose the RGD adhesion sites for osteoclast attachment to 
the matrix178. The structures at which attachment occur, known as 
podosomes, are rapidly assembled and disassembled allowing 
osteoclast movement and resorption across bone surface296. 
Osteoclasts anchor to bone creating a sealed acidic microenvironment 
where mineralized matrix is dissolved, producing the Howship’s 
resorption lacunae. The remaining organic matrix is degraded by 
CTSK311. When its resorption cycles have been completed, osteoclasts 
die by apoptosis and leave the bone surface.  
Following osteoclast-mediated resorption, the resorption pits remain 
covered with undigested demineralised collagen matrix312. Studies 
have shown that mononuclear cells remove the remaining collagen 
and prepare bone surface for subsequent osteoblast-mediated bone 
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formation. This cell type has not yet been identified; it was proposed 
to be a monocytic phagocyte313 but it can also belong to the 
osteoblast lineage312. From a functional perspective both osteal 
macrophages and bone lining cells facilitate events during the 
reversal phase of bone remodeling. Osteal macrophages are resident 
tissue macrophages located close to the bone surface and are 
required for full differentiation and maintenance of osteoblasts314, 
while bone lining cells are terminally differentiated osteoblasts. After 
bone preparation by osteal macrophages and lining cells, the lining 
cells separate from underlying osteocytes and form a canopy over the 
bone to be remodelled, creating the BRC298. The ultimate role of the 
lining cells may be to receive and/or produce coupling signals to allow 
transition from bone resorption to bone formation inside the BMU; the 
nature of this signal remains elusive. It was initially proposed that 
molecules stored within bone matrix, such as IGF-I, IGF-II or TGFβ, 
could act as coupling signals315. However, in mice and humans with 
defective osteoclasts, bone formation is preserved and this finding 
has led to the hypothesis that osteoclasts themselves produce the 
coupling factor135. Several possible coupling mechanisms have been 
proposed, including the soluble molecule sphingosine-1-phosphate 
(S1P) and the bi-directional signalling mediated by ephrin receptor 
B4/ephrin-B2 (EPHB4/EFNB2). S1P is secreted by osteoclasts, 
induces osteoblast precursor recruitment and promotes mature cell 
survival316. EPHB4 receptors are expressed by osteoblasts while 
EFNB2 is located in osteoclasts. Forward signaling through EPHB4 into 
osteoblasts enhances osteogenesis and reverse signaling through 
EFNB2 into osteoclast precursor suppresses osteoclast differentiation 
by inhibiting the osteoclastogenic C-FOS-NFATc1 cascade317. 
However, as osteoblast recruitment and matrix deposition continues 
long after osteoclasts have abandoned the resorption lacunae, several 
mechanisms including both direct contact and soluble signal may be 
required to the coupling process. Mechanical stimulation can induce 
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bone formation signals through osteocytes. Under resting conditions 
osteocytes express SOST318 and, therefore, inhibit bone formation. 
Mechanical strain on bone inhibits osteocyte expression of SOST and 
removes the inhibition of WNT/β-catenin signaling allowing bone 
formation to occur238. 
Once osteoblast progenitors or mesechymal stem cells arrive to the 
resorption lacunae they differentiate and secrete molecules that 
replace the resorbed bone. For bone to assume its final composition, 
hydroxyapatite crystals are incorporated into this newly deposited 
osteoid. Once bone formation is completed and bone surface is 
covered with lining cells, the matrix continues to be mineralized in a 
process dependent on the signaling of osteocytes, particularly on the 
expression of DMP1, phosphate regulating endopeptidase homolog, 
X-linked (PHEX) and FGF23287, 319. The lost SOST expression returns 
towards the end of the remodeling cycle. Following mineralization, 
mature osteoblasts undergo apoptosis, revert to a lining cell 
phenotype or differentiate into osteocytes. When an equal amount of 
lost bone is replaced, the remodeling cycle is completed. The 
termination signal that informs all the machinery that the cycle has 
come to an end is unknown, however osteocytes may have a role in 
regulating this termination phase320. 
 
 
BONE REMODELING DISORDERS 
Trabecular bone is the major site of bone remodeling. In normal 
bone, bone formation and resorption are two balanced and regulated 
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processes in such a way that in adult healthy bone there are no major 
net changes in bone mass or mechanical strength after each 
remodeling cycle. In certain pathological conditions, an imbalance 
between bone formation and resorption may occur, leading to 
abnormal remodeling and bone disorders321. As an example, disorders 
such as OP, osteopetrosis, osteomalacia and Paget’s disease are 
briefly addressed. 
OP is the most common bone metabolic disease and is characterized 
by low bone mass and structural deterioration of bone, leading to 
increased fragility and susceptibility to fractures. About 40% of white 
postmenopausal women are affected by OP and in the context of an 
aging population, this number is expected to increase significantly in 
the near future. The patient with OP have an increased lifetime 
fracture risk, which most commonly occur in the spine, hip or wrist322. 
OP represents a group of distinct pathological conditions classified as 
primary or secondary depending on its aetiology. Primary OP can be 
further divided into two subtypes: post-menopausal (type I), which 
follows menopause in women, mainly due to the loss of the inhibitory 
effect of estrogens on osteoclastogenesis, and age-related (type II) 
that occurs in both genders but is twice more common in women323. 
In contrast, secondary OP is a consequence of an associated disease 
or medication that cause bone metabolism imbalance, such as the 
case of RA. 
OP was operationally defined by the World Health Organization as a 
BMD measured by DXA with a T score lower than 2.5 (more than 2.5 
standard deviations below the peak BMD for the same sex in a given 
population)324. Opposite to DXA scan, which gives us a static image of 
the bone, bone turnover markers reflect the total volume of bone in a 
time frame allowing us to indirectly assess osteoblast and osteoclast 
activity. The biochemical markers of bone turnover are measured 
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both in blood and urine, have origin in the cellular metabolism or are 
products of the matrix remodeling and reflect bone turnover. These 
markers can be divided in two groups according to which function 
they reflect, either resorption or formation31, 34. However, in OP both 
groups are increased due to the coupling mechanisms between bone 
resorption and bone formation325. Currently the most widely used 
markers for bone formation are ALP, bone-specific ALP, OCL and the 
procollagen type I pro-peptides (P1CP and P1NP) (figure 8). On the 
other hand, pyridinium crosslinks (PYD and DPD) and the telopeptides 
of type I collagen (CTX and NTX) reflect bone resorption. For 
remodeling evaluation, the new biomarkers included recently are 
tartrate-resistant acid phosphatase 5b (TRAcP5b), CTSK, BSP and the 
ratio RANKL/OPG326. The major limitation for the clinical utility of all 
these biomarkers is the inter and intra-individual variation.  
 
 
Figure 8 – Bone turnover markers. 
Bone turnover markers can be divided in bone formation and bone resorption 
markers. Formation markers derive from osteoblast metabolism while the 
resorption markers originate from osteoclast action. The RANKL/OPG ratio is a 
marker of osteoclastogenesis.  
(ALP – alkaline phosphatase; BSP – bone sialoprotein;  CTSK – cathepsin K; CTX - carboxy-
telopeptide of type I collagen; DPD – deoxypyridinoline; NTX - amino-telopeptide of type I 
collagen; OCL – osteocalcin; OPG – osteoprotegerin; P1CP - procollagen 1 carboxy-terminal 
peptide; P1NP - procollagen 1 amino-terminal peptide; PYD – pyridinoline; RANK - receptor 
activator of nuclear factor kappa B ; RANKL – RANK ligand; TRAcP5b - tartrate-resistant acid 
phosphatase 5b) 
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The contribution of genetic factors in bone remodeling, BMD 
variability and fracture risk has been extensively studied but without 
consensual results. However, for genes involved in the WNT/β-catenin 
pathway, RANK-RANKL-OPG interaction and estrogen receptors an 
association with both BMD and fracture risk have been established 
327-328. 
Age-related bone loss affects both women and men. Significant 
trabecular loss begins in the early thirties in both genders but after 
menopause women experience acceleration in bone loss due to the 
rapid decline in estrogen after menopause329. In men, age-related 
changes in the levels of sex steroids, including both androgen and 
estrogen, also contribute to the pathogenesis of osteoporosis330. A 
decline in bioavailable estrogen and androgen levels plays a role in 
the development of age-related osteoporosis in men by increasing 
osteoclast formation and function. Moreover, a decline in bioavailable 
androgen levels results in increased bone resorption as well as 
decreased bone formation331-332. In women, it is well established that 
both bone resorption and formation are increased in postmenopausal 
osteoporosis, although the balance of the two processes is shifted 
towards osteoclast-mediated bone resorption333. The variations in 
serum markers of bone turnover have been studied in a group of 
postmenopausal women showing that menopause induces a 79-97% 
increase in bone resorption marker levels and 37-52% increase in 
bone formation334. In early menopause, the acute phase of estrogen 
deficiency, the up-regulation of RANKL on bone-marrow stromal cells 
is associated with increased bone resorption333, 335. However, 
estrogen also stimulates the expression of OPG in mouse osteoblasts 
and stromal cells336 and suppresses the expression of TNF, IL-1 and 
IL-6 in monocytes, osteoblasts and stromal cells337. Therefore, 
estrogen plays a protective role in bone loss by modulation of the 
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RANKL/OPG ratio and inhibition of pro-inflammatory cytokines 
secretion.  
Osteopetrosis is a heterogeneous group of heritable conditions in 
which there is a defect in bone resorption by osteoclasts. The 
decrease in osteoclast activity also affects the shape and structure of 
the bone by altering its capacity to remodel during growth. In the 
most severe forms, the medullary cavity is filled with new bone, with 
little space remaining for hematopoietic cells. As a consequence of 
altered osteoclastic behavior osteopetrosis is associated with 
increased skeletal mass due to abnormally dense bone338. This 
contributes to the brittleness of bones and propensity for fractures 
characteristic of this disease. Osteopetrosis is genetically 
heterogeneous with autosomal dominant and recessive forms. There 
is a wide spectrum of phenotypes, the most severe caused by 
autosomal recessive inheritance339. Osteoclast development requires 
the presence of two growth factors, M-CSF and RANKL, and absence 
of either molecules leads to severe osteopetrosis in rodents, with lack 
of osteoclasts formation340-341. Also, loss-of-function mutations in 
either RANKL or RANK have recently been identified in osteoclast-
poor cases of osteopetrosis342-343. Although a substantial percentage 
of osteopetrosis patients have no identifiable gene defect, three 
mutations that cause abnormal acidification of the resorption lacunae 
have been identified. The most common, found in 50-60% of the 
patients, results in a defect in the osteoclast vacuolar H+-ATPase 
proton pump. The second most clinically significant form occurs in 10-
15% of the patients with severe autossomal recessive osteopetrosis 
and affects CLCN7, a gene encoding the osteoclast specific chloride 
channel. Carbonic anhydrase II dysfunction is a feature of autossomal 
recessive osteopetrosis but accounts only for a small proportion of 
patients339, 344. 
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Rickets and osteomalacia, also known as “soft bones” diseases, are 
characterized by a defect of mineralization due to calcium and/or 
phosphate deficiencies. Rickets is a disease of the growing skeleton 
and affects the bones in children, which are defective in strength and 
deformed. The prototype of this disease is vitamin D deficiency 
(nutritional) rickets. Osteomalacia is the adult counterpart5. In both 
diseases there is insufficient calcium and/or phosphorus to mineralize 
the skeleton. There may be less overall volume of bone, but more 
importantly, the bone fails to mineralize properly. Trabeculae are 
surrounded by unmineralized osteoid forming the so-called “osteoid 
seams”. Moreover, bone histomorphometry studies have shown that 
the mineralization lag time is higher than 100 days in rickets or in 
osteomalacia, contrasting with the normal 80-90 days5. Therefore, 
patients with osteomalacia present osteopenia or low BMD and 
frequently elevated levels of PTH, hypophosphatemia and elevated 
levels of ALP in circulation345. In a report of five cases with 
hypophosphatemic osteomalacia the authors reported an increase in 
the levels of ALP, both total and specific for bone, low levels of OCL 
and a slight increase in the collagen metabolism markers, particularly 
P1NP346. In vitamin D deficiency there is a reduction in the absorption 
of calcium from the gastrointestinal tract and an increase in the renal 
secretion of calcium that lead to lowering of blood calcium. This 
triggers a secondary hyperparathyroidism which brings the serum 
calcium to a normal level, but at the expense of bone loss347. The 
consequences of vitamin D deficiency in bone are inhibition of 
osteoblast progenitors, increase of RANKL and decrease of OPG. The 
immediate consequence is enhanced bone turnover and increased 
bone resorption321, 348. Mutational analysis in two families with 
autosomal recessive hypophosphatemic rickets showed the presence 
of mutations affecting the DMP1 start codon and a 7bp deletion 
disruption of the gene C-terminus. In addition, studies in mice 
demonstrated that absence of DMP1 resulted in defective osteocyte 
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maturation leading to pathological changes in bone mineralization287. 
In another family with X-linked hypophosphatemic rickets analysis 
revealed a deletion of 52143bp including exons 1 to 3 in the PHEX 
gene349. 
Paget’s disease is characterized by a focal increase in bone turnover 
that affects one or more bones of the skeleton and becomes more 
prevalent with aging. Paget’s disease shows autosomal dominant 
inheritance and familial clustering has been recognized for over 50 
years350. Between 15-40% of the patients have positive family history 
of the disease and studies have shown that the risk for relatives to 
develop Paget’s disease is increased between 7-10 times, compared 
with the risk of relatives of controls351. Paget’s disease is primarily a 
disorder of increased bone resorption with a secondary increase in 
osteoblast activity and new bone formation. The resulting trabecular 
bone is abnormal and disorganized352. A large histomorphometric 
study showed high bone turnover with a significant increase in bone 
resorption and bone formation indices leading to increased bone 
volume. A malignant transformation to osteosarcoma was observed in 
0.8% of the patients353. Biochemical markers of bone turnover are 
increased in Paget's disease354 and the same was observed for 
TRAcP5b355. Moreover, in Paget’s disease woven bone can be 
frequently found, with an irregular arrangement of collagen fibers. 
Therefore, the ratio of α-CTX/β-CTX is markedly increased, both in 
bone and urine356. The primary cellular abnormality resides in 
osteoclasts which have increased number of nuclei, are markedly 
increased in number and size, have an increased rate of formation 
and an increased bone resorption capacity per cell. In addition, 
osteoclast precursors from patients with Paget’s disease have 
increased responsiveness to RANKL357. Genetics play an important 
role in this bone remodeling disorder. In about one-third of the cases, 
Paget’s disease is inherited as an autosomal dominant disease with 
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incomplete penetrance339. Several genetic loci have been linked to 
Paget’s disease358-359 but mutations in the genes RANK and 
particularly in sequestosome-1 (SQSMT1) have been reported to be 
associated with the disease360-361 and are common causes of the 
classical Paget’s disease362. SQSMT1 encodes p62, which is a scaffold 
protein in the NF-κB signaling pathway363. A total of twenty different 
SQSMT1 mutations have been identified, all of which cluster around 
the ubiquitin-associated domain of the protein product of this gene. 
SQSTM1 mutations are strongly associated with disease severity and 
complications of Paget’s disease364. Between 30-50% of the patients 
with familial Paget’s disease and 10-30% of patients without family 
history of the disease have mutations in this gene365. Studies in mice 
with targeted inactivation of SQSMT1 have impaired 
osteoclastogenesis in response to RANKL in vivo, suggesting that 
SQSMT1 plays a key role in regulating osteoclastogenesis366. 
Osteoclasts derived from peripheral blood monocytes from patients 
with Paget’s disease were in higher numbers, contained more nuclei, 
were more resistant to apoptosis and exhibited greater bone-
resorption capacity, compared to cells from healthy donors367. 
Overall, bone remodeling is a tightly regulated balanced process 
between bone resorption and formation. However, alterations to this 
equilibrium lead to bone remodeling disorders. Nowadays, the 
challenge is to replace the lost balance. 
 
  
60 
 
OSTEOIMMUNOLOGY 
 
The term osteoimmunology was used for the first time in 2000368 to 
describe the interaction of cells from the immune and skeletal 
systems for promoting osteoclastogenesis. This connection between 
bone and immune systems is not surprising, since precursors of 
immune cells reside in bone marrow, thus in the same environment 
as differentiated bone cells. Moreover, osteoclasts are of 
hematopoietic origin. Thus, a new concept is emerging in which bone 
exerts a quality control on immune responses by controlling the 
availability of hematopoietic stem cells (HSC)369. Osteoblasts play a 
crucial role in stem cell maintenance due to an intimate cell-cell 
contact via integrins370-371. Moreover, RUNX2-deficient mice are 
devoid of osteoblasts and are also characterized by the absence of 
bone marrow, although they show normal hematopoietic 
development in liver and spleen, suggesting an important role of 
osteoblasts in HSCs homing into the bone marrow cavity372. 
Osteoblasts can also control the pool of HSCs available by producing 
OPN, which inhibits their proliferation373-374. OPN is also required for 
the proper localization of the HSCs373. Adhesion of HSCs and 
osteoblasts appears to be mediated by interaction of N-cadherin and 
β-catenin375. In addition, TEK tyrosine kinase endothelial (TIE2) on 
HSCs and Angiopoietin-1 on osteoblasts also play a role in the 
inhibition of cell division of HSCs, while maintaining their capacity for 
self-renewal376. More recently, osteoclasts have been involved in the 
mobilization of HSCs. Indeed, stimulation of bone resorption 
increases the number of immature HSCs in circulation, suggesting 
that osteoclasts, by destroying the architecture of the niche, play a 
key function in mobilizing HSCs377. When mobilized, HSCs migrate 
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through the bone marrow to meet the endothelial cells of the sinusoid 
vessels. These cells also form a niche for HSCs and support their 
proliferation, differentiation, as well as entry into the circulation370. 
Immune and skeletal systems have several regulatory factors in 
common, such as cytokines, transcription factors and receptors 
(figure 9). Consequently, these two systems interact with each other 
both in physiological and pathological conditions. All mammals are 
constantly being challenged by a variety of infectious agents, which 
produce some level of constant low grade immune system activation; 
therefore it is not difficult to imagine that crosstalk occurs throughout 
life between activated lymphocytes and bone cells. Furthermore, as 
we age there is accumulation in the bone marrow of memory T cells, 
which express RANKL on their surface. It is believed that these cells 
might influence bone turnover and be responsible for some of the 
changes that occur in the skeleton with aging378. 
Osteoblasts seem to have antigen-presenting properties, since cell 
lines were shown to express human leukocyte antigen (HLA) 
molecules besides the adhesion molecules CD54 and CD166, which 
are upregulated in the presence of IFN-γ and can activate T cells. 
Furthermore, osteoblasts express members of the toll-like receptor 
(TLR) family, in particular TLR-4, 5 and 9, indicating an active role in 
host immune response379. On the other hand, osteoclasts can send 
regulatory signals to T cells and potently suppress T cell response to 
mitogenic stimuli. They also have the capacity to attract and retain T 
cells at the bone surface, thus revealing a new role for osteoclasts380. 
These bone cells can also cross-present antigens to CD8+ T cells, 
showing that osteoclasts are not just regulated by T cells but they 
can also modulate these cells forming a feedback control loop381. 
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Figure 9 – Interaction between bone and the immune system. 
Osteoclastogenesis makes use of three signals, RANK-RANKL, M-CSF and a 
costimulatory signal. However, there are also several factors produced by immune 
cells that also influence bone remodeling. Immune cells express RANKL and, 
therefore, can support osteoclastogenesis; on the other hand, these cells secrete 
several cytokines that can have either a pro-osteoclastogenic or an anti-
osteoclastogenic effect.  
(DC – dendritic cell; HSC – hematopoietic stem cell; M-CSF - colony stimulating factor 1 
(macrophage); MSC – mesenchymal stem cell; OPG – osteoprotegerin; PPARγ – peroxisome 
proliferator activated receptor γ; RANK - receptor activator NF-κB; RANKL – RANK ligand; Th 
– T helper) 
 
 
RHEUMATOID ARTHRITIS AND BONE 
RA is a chronic inflammatory disease that targets the synovial 
membrane, cartilage and bone. It affects around 0.5-1% of the world 
population and is associated with significant morbidity and increased 
mortality382-383.  
In this disease, autoimmune phenomena, which manifest as the 
production of antibodies specific for immunoglogulin G (IgG, also 
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known as rheumatoid factor) or specific for cyclic citrullinated 
peptides, precedes the clinically detectable onset of arthritis. In some 
patients these markers emerge years before the onset of the disease 
and probably contribute to its development and perpetuation384. 
Several genes have been proposed to be associated with 
susceptibility and severity of RA385; in fact, studies in twins suggest 
that genetic factors account for 60% of the RA onset386. There are 
two genes strongly associated with RA, the HLA system387-390 and the 
protein tyrosine phosphatase non-receptor type 22 (PTPN22)391. A 
recent study has shown that citrullination generates “altered-self” 
peptides that are recognized preferentially by a subset of HLA-DR1 
alleles that encode a conserved sequence of alleles known as the 
“shared epitope”392. Several other genes were found to be related 
with RA in a genome-wide association study, however only CD28, PR 
domain zinc finger protein 1 (PRDM1) and the attachment complex 
CD2/CD58 were considered risk factors for the disease393. In 
genetically susceptible individuals, specific environmental factors such 
as smoking habits, trauma or infection can activate potentially 
pathogenic immune pathways, contribute to disease development and 
its perpetuation, leading to chronic inflammation, joint destruction 
and systemic manifestations382. 
After the onset of RA, the normally hypocellular synovial membrane 
becomes hyperplasic, comprising a superficial lining layer of synovial 
fibroblasts and macrophages that expands from just one layer to 
several layers, covering an interstitial zone that contains a marked 
cellular infiltrate which includes synovial fibroblasts, macrophages, 
mast cells, CD4+ and CD8+ T cells, natural killer (NK) cells, natural 
killer T (NKT) cells, B cells and plasma cells. The inflamed synovium 
invades adjacent cartilage and bone, promoting joint destruction, 
which is mediated by the activities of osteoclasts, chondrocytes and 
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synovial fibroblasts. In turn, joint damage is a source of neo-
antigens, thereby promoting further autoimmune reactivity.  
The inflammatory environment that occurs in RA induces bone 
remodeling disturbances, contributing not only to bone erosions but 
also to the development of secondary OP. In fact, RA patients have 
an increased risk of vertebral fractures, which is independent of BMD 
and corticosteroid use394. In addition, a high hip fracture risk was also 
noted in RA patients not exposed to corticosteroids395. Thus, RA itself 
seems to predispose to fractures although the underlying 
mechanisms are not yet completely understood. 
During chronic inflammation, the balance between bone resorption 
and formation is skewed towards osteoclast-mediated bone 
resorption. Moreover, in inflamed joints, osteoclasts are located in the 
interface between the inflamed synovium and bone396. We can 
consider two essential key mechanisms for the formation of 
osteoclasts in the joints, the accumulation of precursors and their 
stimulation to differentiate into the osteoclast lineage. It is not clear 
whether the osteoclasts that enter the inflamed joint are already 
committed to the osteoclast lineage or are triggered locally within the 
synovium. Nevertheless, experimental evidences support the view 
that the peripheral monocytic population changes during 
inflammation towards an increase in the number of osteoclast 
precursors397. In collagen-induced arthritis (CIA) mice, the number of 
cells expressing RANK increases as arthritis progresses and, in areas 
of abundant RANK+ cells, TRAP+ multinucleated osteoclasts are also 
present. Sites of RANK expression were also co-localized with 
RANKL398, which appeared to be overexpressed in pannus tissue from 
active RA patients399. Interestingly, RANK and RANKL are also 
essential for the development of secondary lymphoid tissues400. 
Denosumab, a fully humanized monoclonal anti-RANKL antibody, 
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administered in association with methotrexate reduced erosion scores 
at 6 months after administration. The protection from focal bone 
erosion was accompanied by a decrease in bone turnover markers 
and an increase in BMD at 12 months401. Moreover, in another study, 
the authors reported that these effects were independent of 
concomitant bisphosphonate or glucocorticoid use402. Denosumab 
therapy in RA patients was also reported to decrease progression of 
erosions in the hands while increasing BMD and reducing cortical 
bone loss at 12 months after therapy403-404.Therefore, as in 
physiological conditions, RANKL-RANK-OPG system is a major player 
in bone resorption in RA405. 
It is presently accepted that in RA both innate and adaptative 
immune responses are disturbed. Cytokines are implicated in both 
early and late phases of the pathogenesis of RA, promoting 
perpetuation of immune activity, maintaining chronic inflammatory 
synovitis and driving the destruction of adjacent joint tissues406. 
TNF407-408, IL-1409-410 and IL-6411-412 are among the most important 
mediators of rheumatoid arthritis pathogenesis. Activated T and B 
cells are present in rheumatoid synovia413-414 and synovial 
inflammation is the result of complex interactions between immune 
cells. Antigen-presenting cells communicate with T cells but their full 
activation requires a second co-stimulatory signal mediated by CD28-
B7 receptor family. B cells participate in this complex environment by 
functioning both as antigen-presenting cells and as antibody-
producing cells. Macrophages are activated by T cells and are key 
producers of pro-inflammatory cytokines such as TNF, IL-1 and IL-
6382. On the other hand, cytokines regulate the phenotype of effector 
and regulatory T cells in the synovium. T cell activation is critical to 
the initiation and maintenance of RA and maximum T cell responses 
usually require co-stimulatory signals. Abatacept, a chimeric fusion 
protein composed of IgG1 Fc and extracellular domain of Cytotoxic T-
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Lymphocyte Antigen 4 (CTLA4) that blocks T cell activation by 
disrupting the co-stimulatory signal, is effective for RA treatment by 
interfering with co-stimulation415. RANKL is not only expressed by 
osteoblasts, but also by several immune system cells, particularly by 
activated T cells, suggesting that these cells have a role in 
osteoclastic bone resorption416. However, some T cells are classical 
anti-osteoclastogenic cells as they produce cytokines that inhibit bone 
resorption, especially IFN-γ, the most potent inhibitor of RANKL 
signalling by downregulation of TRAF6417.  
DCs express RANK and they can be found in RA joints. It is thought 
that they mediate osteoimmune interactions indirectly by activating T 
cells to produce RANKL, which can then lead to osteoclastogenesis418. 
Moreover, DCs can even transdifferentiate in vitro into osteoclasts in 
the presence of M-CSF and RANKL and the resulting cells express the 
typical markers of osteoclasts419-421. 
Several studies have classified rheumatoid arthritis as a Th1 
mediated disease and, therefore it was thought to be driven by a 
population of T cells producing interferon IFN-γ, lymphotoxin (LT)-β 
and TNF422-423. However, a new model is emerging that implicates 
Th17 cells as crucial effectors, since inhibition of IL-17 or its 
overexpression in mouse joints suppress or worsen joint inflammation 
and damage, respectively424. IL-17 drives neutrophil differentiation, 
maturation and activation, as well as monocyte and synovial 
fibroblast activation and cytokine, chemokine, prostaglandin and MMP 
production425. A synergistic effect has been observed with low 
concentrations of IL-17, IL-1β and TNF, which together lead to 
synovial fibroblast activation and cytokine production, indicating a 
pathogenic role for these inflammatory cascades426-427. In the 
synovial fluid of RA patients, OPN levels correlate with IL-17 
production and the frequency of Th17 cells and OPN play a direct role 
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in Th17 cell differentiation in vitro428. Recently, Th17 cells were 
identified as a typical pro-osteoclastogenic Th subset429 due to the 
fact that they express RANKL at higher levels than Th1 or Th2, do not 
produce high amounts of IFN-γ and secrete pro-inflammatory 
cytokines. In addition, IL-17 induces RANKL expression on 
osteoblasts, and also enhances inflammatory cytokines production by 
other cells, thereby increasing RANKL expression and activity424, 430. 
Moreover, IL-17 induces the synthesis of MMPs, inducing bone and 
cartilage degradation431. IL-17 overexpression in CIA mice not only 
enhances RANKL expression, but also upregulates RANKL/OPG ratio 
in the synovium432. Treatment with a neutralizing anti-IL-17 antibody 
significantly reduces arthritis severity and suppresses joint damage. 
In addition, IL-6 levels are markedly reduced after treatment, as well 
as the number of IL-1β and RANKL positive cells in the synovium433. 
By comparing functional levels of IL-17 in synovial explants cultures 
from RA, osteoarthritis (OA) and healthy joints, it was found that IL-
17 is spontaneously produced by cells from RA synovium434. In 
another study, authors described an enrichment of IL-17 producing 
CD4+ T cells in the synovial fluid from RA patients as compared to 
blood. Moreover, Th17 cells from RA synovial fluid produce more TNF 
than the same cells from blood435 and both the frequency of Th17 
cells and IL-17 levels are increased compared to healthy joints436.  
Regulatory T cells (Treg) represent another T cell subpopulation with 
the main function of suppressing immune system activation437. 
Naturally occurring Tregs have been detected in the synovium of 
patients with active disease and particularly in synovial fluid438-439 
and, in some cases, in peripheral blood440. These observations raised 
the question of whether Tregs that are present in RA joints are 
dysfunctional or are functional but unable to prevent the disease441. 
Indeed, there is evidence for both effective and dysfunctional Treg 
cell activity in this disease setting. The support for the efficacy of 
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Tregs arose from studies of patients with juvenile idiopathic arthritis 
(JIA), where higher numbers of circulating Tregs were associated with 
mild forms of the disease442. On the other hand, Treg cells isolated 
from RA patients exhibit reduced suppressor function443-444 but after 
anti-TNF treatment, these cells acquire the ability to suppress 
cytokine production by effector cells443. Treg cells, which express high 
levels of CTLA4, block osteoclast formation independently of RANKL 
by binding to CD80 and CD86 in the pre-osteoclasts445. Tregs also 
secrete anti-inflammatory cytokines like IL-4, IL-10 and TGFβ that 
also suppress osteoclastogenesis446-448. Recently, CTLA4 from Treg 
cells was reported to suppress in vitro osteoclastogenesis and 
recombinant CTLA4 was shown to reduce in vivo resorption in an 
arthritis model449-450. Tregs prevent the development of CIA which is 
accompanied by a decrease in serum levels of the pro-inflammatory 
cytokines TNF and IL-6. Moreover, anti-osteoclastogenic cytokines, 
such as GM-CSF, IFN-γ, IL-5 and IL-10 were drastically increased, 
suggesting that Treg cells not only inhibit osteoclastogenesis but also 
regulate cytokine production and improve clinical symptoms in the 
CIA mice model451. In another study, it was shown that blood 
markers of bone resorption inversely correlate with the amount of 
circulating Treg cells in healthy controls and RA patients, further 
demonstrating that Tregs may control bone destruction in vivo452. A 
reciprocal relationship was also found between Th17 cells and Tregs, 
suggesting that the factors that lead to the recruitment or survival of 
these two cell populations will lead to a predominance of either one of 
the subtypes. These data support the hypothesis that Th17 cells are 
key players in the pathogenesis of inflammatory arthritis and bone 
erosions453. Therefore, in pathological conditions, the effects of T cells 
on osteoclastogenesis depend on the balance between positive and 
negative regulating factors produced by them. 
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Naïve and memory B cells infiltrate and accumulate in the synovial 
tissue, where there is continuous activation of selected B cell clones 
with a high migratory capacity454. In addition to autoantibody 
production and immune-complex formation, B cell lineage also 
contributes to RA pathogenesis by the production of cytokines and 
chemokines such as IL-6, IL-10 and LT-β and through their role as 
antigen-presenting cells. Of interest, B cell depletion therapy with 
Rituximab415 prevents the formation of ectopic germinal centres and 
the optimal activation of T cells455 and markedly diminished clinical 
signs and symptoms of RA. Bone also interacts with B cells as RANKL 
is known to influence their development, increasing pro-B cell 
proliferation456. Progression of B cells along the lymphopoiesis 
requires physical contact with osteoblasts and stromal cells457-459. 
Interaction between B cell progenitors and stromal cells involves 
growth factors, chemokines and their receptors, among which 
chemokine (C-X-C motif) ligand 12 (CXCL12) and IL-17 are crucial460-
461. In mice lacking CXCL12, the number of B cell progenitors is 
severely reduced in the bone marrow461. B cells from osteoporotic 
bone marrow show a higher density of RANKL than healthy 
individuals335. Moreover, it was reported that B cell progenitors have 
the ability of differentiating into osteoclasts in vitro, and peripheral 
blood B cells can support osteoclastogenesis462. B cells also cooperate 
with T cells in basal bone turnover. B cells regulate bone homeostasis 
through OPG production, which is promoted by T cells via CD40-
CD40L costimulation. B cell knockout mice exhibit severe reduction in 
OPG levels and elevated bone resorption420, 463. Studies in animal 
models have shown that the loss of OPG increases pro and mature B 
cells, while the loss of RANKL or RANK has the opposite effect464. 
Moreover, in osteopenic mice B cell number decreased specifically by 
a reduction in the expression of CXCL12 and IL-7 by stromal cells, 
associated with lower osteoblastic engagement determined by the 
numbers of ALP positive cells465. 
70 
 
Recent data increasingly implicate other innate immune response 
effector pathways in rheumatoid synovitis. Innate immune pathways 
remain of critical importance throughout the course of the disease466. 
Natural killer (NK) cells act as a bridge between the innate and the 
adaptative immune systems and respond to a variety of insults 
through cytokine secretion and cytolytic activity467. Recently, NK cells 
were shown to express both RANKL and M-CSF and appear frequently 
associated with CD14+ monocytes in RA synovium. Moreover, when 
NK cells are co-cultured with monocytes, they trigger their 
differentiation into osteoclasts, in a RANKL and M-CSF dependent 
process. It was also shown that depletion of NK cells in CIA mice 
reduces the severity of arthritis and prevents bone erosion468. Mast 
cells are similarly implicated at the crossroad of innate and adaptative 
synovial immunity. They are widely distributed in rheumatoid arthritis 
synovial tissue and express several proteases and pro-inflammatory 
cytokines, including IL-17469-470. Neutrophils are present in high 
numbers in synovial fluid and traffic through the synovial membrane. 
Although their primary role in the pathology of RA is disputed, they 
synthesize a wide variety of cytokines including TNF, IL-1, IL-18, IL-
15, IL-6 and B-cell activating factor (BAFF), and therefore could 
support a range of pathological events471. Neutrophils rapidly invade 
inflammatory sites where they act as first-responders by 
phagocytosis and release of toxic and pro-inflammatory molecules472. 
One of the most important chemotactic factors for neutrophils is IL-8, 
which is produced in response to inflammatory stimuli by osteogenic 
cells, linking osteoblasts with neutrophil infiltration473. Neutrophil-
mediated inflammatory response appears to suppress osteoblastic 
differentiation from MSCs while enhancing chondrogenesis474. In 
addition, RA synovial fluid neutrophils strongly express RANKL and 
activate osteoclastogenesis in coculture systems and direct cell-cell 
contact between neutrophils and osteoclasts was observed420, 475. In 
another study, neutrophils from RA synovial fluid not only expressed 
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RANKL but also RANK and OPG, although peripheral neutrophils only 
express RANKL476. TNF is clearly of primary importance in the 
pathogenesis of rheumatoid arthritis406. This cytokine is present in 
most synovial biopsies and its inhibition suppresses several arthritis 
models, whereas overexpression of TNF induces spontaneous erosive 
inflammatory arthritis477.  
Immune cells have the ability to induce osteoclast differentiation and, 
consequently, bone resorption. These cells are also known for 
producing a variety of pro-inflammatory cytokines that contribute to 
bone damage by potentiating the effects of the RANK-RANKL 
signalling405. TNF, IL-1β, IL-3, IL-6, IL-7, IL-11, IL-15 and IL-17 
potentiate bone loss either by increasing osteoclast generation and 
activation or by inducing RANKL expression on osteoblasts. On the 
other hand, IL-4, IL-5, IL-10, IL-12, IL-13, IL-18, IL-33, IFN-α, IFN-β 
and IFN-γ are inhibitors of osteoclastogenesis by blocking RANKL 
signalling462. IL-6 is an important monocyte-derived effector cytokine. 
Its levels were found elevated in synovial fluid of RA patients and 
were related to disease activity411. Moreover, IL-6 knockout mice are 
protected from developing joint symptoms in an arthritis model478, 
and in humans blockade of the IL-6 signalling has been accomplished 
with an anti-IL-6 receptor (IL-6R) antibody (tocilizumab) with very 
good results479-480. IL-6 is a pro-inflammatory cytokine with pro-
osteoclastogenic effects which not only contributes to the 
inflammatory response in RA but also induces osteoclast 
differentiation by promoting RANKL expression481. Blockade of IL-6R 
reduced osteoclast differentiation and bone resorption in monocyte 
cultures stimulated with RANKL. Moreover, IL-6R blockade in TNF-
transgenic (tg) mice did not inhibit joint inflammation but strongly 
reduced osteoclast formation in swollen joints as well as bone 
erosions, suggesting an independent effect on bone metabolism482. 
Targeting IL-6R in a CIA mouse model results in a decrease in Th17 
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cells recruitment to the affected joint that is paralleled by a decrease 
in inflammatory activity483. In a CIA monkey model treated with 
tocilizumab, there was suppression of RANKL production and a 
decrease in the number of osteoclasts484. Moreover, patients with 
moderate to severe RA under tocilizumab therapy showed marked 
reduction in bone and cartilage degradation markers and an increase 
in bone formation four weeks after infusion485. IL-1α and IL-1β are 
expressed in the synovium of patients with RA486 and, similar to the 
response in adjuvant arthritic rats, RA patients treated with IL-1Ra 
showed a modest anti-inflammatory activity486-487. Interestingly, IL-
1β is a stimulator of TRAF6 expression in the osteoclast, thereby 
potentiating RANKL-RANK signalling cascade488, whereas IFN-γ is 
known to downregulate TRAF6 by proteosomal degradation 
abrogating osteoclast formation417. IL-1β can also indirectly facilitate 
osteoclastogenesis by acting on the osteoblast inducing RANKL 
expression430. Arthritis in IL-1β-deficient mice is not associated with 
the occurrence of erosions489-490, and even arthritic joint destruction 
of TNF-tg mice can be inhibited by anti-IL-1β-receptor antibody491.  
TNF favours leukocyte and endothelial cell activation, synovial 
fibroblast activation and survival, pain-receptor sensitization and 
angiogenesis, which together represent key pathological features of 
rheumatoid arthritis406. Therapeutic blockade of TNF yields clinical 
responses in approximately 60% of patients with established 
rheumatoid arthritis492 and it results in a rapid decrease of IL-6 levels 
and acute-phase proteins, suppression of leukocyte migration and 
recovery of regulatory T cell function443, 493. Osteogenic differentiation 
of MSCs is blocked by IL-1β and TNF that not only suppress 
mineralization but also inhibit the expression of ALP, type I collagen, 
RUNX2 and OSX, blunting osteoblast formation494. Moreover, TNF 
increases proliferation and differentiation of pre-osteoclast in the 
presence of RANKL. TNF alone cannot induce osteoclast formation but 
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combined with IL-1β495 or TGFβ496 it results in osteoclastic activity 
independent of RANKL. TNF is a potent inhibitor of osteoblast 
differentiation from its precursor cells, acting during the early stage 
of phenotype selection497. In vitro, TNF induces reduction in ALP 
activity, OCL expression and type I collagen synthesis194. Osteoblasts 
treated with TNF were also unable to regulate matrix 
mineralization498.  
Other factors contribute to the complex regulation of osteoclast 
differentiation. GM-CSF inhibits osteoclast differentiation by 
suppressing the transcription factors FOS and FOS-like antigen 1 
(FRA-1), which would otherwise drive monocytes to differentiate into 
DCs499. Moreover, the combination of IL-4 and GM-CSF abolished 
monocytic differentiation into osteoclasts and induced DC 
differentiation, even in the presence of M-CSF and RANKL. GM-CSF 
and RANKL up-regulate TACE activity in monocytes, causing 
ectodomain shedding of M-CSF receptor, resulting in the inhibition of 
osteoclast formation500. The role of TGFβ on osteoclastogenesis is 
somehow controversial. TGFβ signalling, which primarily involves the 
Smad pathway, induces osteoclast apoptosis through up-regulation of 
BCL2-like 11 (BIM)501. On the other hand, the canonical TGFβ 
receptor complex is involved in the survival response and TGFβ-
induced NF-κB activation is essential for TGFβ-mediated osteoclast 
survival502. Moreover, TGFβ induces osteoblast proliferation as an 
immediate response but decreases matrix production as a late 
response. Expression levels of osteoblast markers are down-regulated 
upon TGFβ stimulation and they acquire an osteoclast-recruiting 
phenotype503. In T cells, TGFβ by itself does not induce the expression 
of RANKL, but it can be synergistically induced by the combined 
stimulation with TGFβ and T cell receptor (TCR), significantly 
contributing to bone destruction during autoimmune arthritis504. 
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Another important feature of rheumatoid synovitis is the deficiency of 
regulatory cytokines, which contributes to an imbalance between pro 
and anti-inflammatory stimuli in the joints. Therefore, although anti-
inflammatory cytokines are expressed by synovial mononuclear cells, 
they are not present in sufficient concentrations to inhibit the 
dominant pro-inflammatory milieu505.  
Although M-CSF and RANKL are essential factors for osteoclast 
differentiation, it was hypothesized that costimulatory molecules like 
immunoglobulin-like receptors (PIR) are the third essential factor 
required for osteoclastogenesis (figure10). Among these molecules 
are OSCAR and PIR-A, that signals through FcRγ. Interestingly, 
OSCAR and PIR-A trigger receptors expressed on myeloid cells 
(TREM)-2 and signal-regulatory protein (SIRP)-β1506, that signal 
through DNAX-activation protein 12 (DAP12)507, and both activate an 
intracellular calcium cascade. This signalling leads to 
dephosphorylation of calcineurin, thereby activating the auto-
amplification of NFATc1, which consequently promotes osteoclast 
differentiation430. Concordantly, DAP12-deficient mice develop 
osteopetrosis and in vitro osteoclast differentiation yield immature 
cells with attenuated bone resorption activity507. Moreover, DAP12-/-
FcRγ-/- bone marrow cells fail to differentiate into multinucleated 
osteoclasts in vitro and show impaired phosphorylation of the Syk 
tyrosine kinase, suggesting that the recruitment of Syk to 
phosphorylated immunoreceptor tyrosine-based activation motif 
(ITAM) is critical for osteoclastogenesis508. Because DAP12 has no 
extracellular binding domain it must combine with a cell surface 
receptor for signal transduction. From the 15 different DAP12-
associating receptors, DAP12-associating lectin (MDL)-1 receptor was 
identified as a key regulator of synovial injury and bone erosion 
during autoimmune joint inflammation509. Therefore, FcRγ and DAP12 
are adaptor molecules that associate with immunoglobulin-like 
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receptors helping their expression and transducing signals through 
ITAM506, 510. RANKL also interacts with ITAM by inducing its 
phosphorylation, thus increasing expression of PIR and enhancing 
ITAM signal462. 
 
 
Figure 10 – The three signals of osteoclastogenesis. 
Although RANK-RANKL and M-CSF are essential factors for osteoclastogenesis, 
currently it is believed that this process needs a third signal. This co-stimulation is 
mediated through immunoglobulin-like receptors present in the pre-osteoclast that 
are stimulated by a yet unknown ligand on the osteoblast.  
(C-FMS - colony stimulating factor 1 receptor; M-CSF - colony stimulating factor 1 
(macrophage); PIR - immunoglobulin-like receptor; RANK - receptor activator NF-κB; RANKL 
– RANK ligand; TRAF6 – tumor necrosis factor receptor-associated factor 6) 
 
Further modulation of osteoclastogenesis is provided by TLRs. TLR 
expression was detected on bone cells and direct signalling through 
TLR activates a TRAF6 mediated cascade leading to the activation of 
transcription factors such as NF-κB and AP-1 family factors and to the 
synthesis and release of pro-inflammatory cytokines456, 511-512. 
However, the outcome of TLR activation depends on the stage of 
differentiation of the osteoclast. In early precursor cells, TLR inhibit 
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osteoclastogenesis, but in cells that have already started to develop 
into osteoclasts TLR is a potent pro-osteoclastogenic factor. In 
mature osteoclasts, TLR signalling promotes cell survival. On the 
other hand, osteoblasts were also found to express TLR, namely TLR-
4, TLR-5 and TLR-9, and exposure of these cells to pathogen-
associated molecular patterns (PAMPs) induces the secretion of pro-
inflammatory cytokines511. Moreover, TLR-9 is activated by CTSK, a 
protease expressed by osteoclasts and, although in low levels, in 
DCs. Inhibition of CTSK suppresses autoimmune inflammation in the 
joints as well as osteoclast-mediated bone resorption. Moreover, 
targeted disruption of CTSK resulted in defective TLR-9 signalling in 
DCs and attenuated induction of Th17 cells, suggesting that CTSK 
plays an important role in the immune system513. In fibroblast-like 
synoviocytes (FLS) from RA patients, TLR-2, TLR-3 and TLR-4 
activation induces not only RANKL expression, but also production of 
IL-1β. However, it had no effect on IL-17 or TNF. Co-culture of 
monocytes with TLR-3 activated RA FLS, increased the expression of 
TRAP, RANK, CTSK, CALCR and MMP-9, reflecting the differentiation 
of monocytes into osteoclasts514-515. In fact, MMP-9 is strongly 
expressed in osteoclasts from RA patients and cleaves both soluble 
and insoluble type I collagen516. At the molecular level, TLR ligands 
suppressed osteoclastogenesis by inhibiting RANK expression and 
down-regulating the M-CSF receptor517. Therefore, TLRs contribute to 
the modulation of osteoclastogenesis by modulating the function of 
both osteoblasts and osteoclasts511. 
In RA joints, the presence of osteoclasts and pro-inflammatory 
cytokines leads to pathological bone destruction, joint damage and 
loss of function. Although an in vitro study showed that the capacity 
to generate osteoclasts varies greatly among individuals, RA patients 
presented significantly higher numbers and larger osteoclasts after 21 
days of culture than controls518 or patients with OP519. Higher 
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osteoclast numbers associate with increased resorptive activity, 
further accounting for the excessive bone loss observed in RA520. 
Moreover, RA patients present both higher percentage of CD14+ 
osteoclast precursors and lower apoptosis than the control group, 
suggesting that these two factors contribute to the large number of 
cells found in RA518. Osteoclasts formed from precursors obtained in 
RA patients show increased bone-resorbing activity compared to 
controls521 and bone resorption by cells isolated from synovial fluid 
precursors was even higher522. In RA, there is little evidence of bone 
erosion repair, which is surprising considering that bone formation is 
coupled to bone resorption and increased rate of resorption should be 
accompanied with increased formation. Furthermore, in arthritic 
bone, mineralization of newly formed bone in areas adjacent to 
inflammation sites is reduced compared with bone surfaces adjacent 
to normal bone marrow, which suggest that the inflammatory tissue 
impairs osteoblast activity. In arthritic bone, there are abundant 
RUNX2-expressing cells but a limited number of cells expressing ALP 
and OCL indicating that osteoblasts have reduced capacity to form 
bone. Therefore, osteoblast activity at sites of focal bone erosion does 
not compensate the excessive osteoclastic resorption leading to an 
uncoupling of these two activities523. The sequence and quantity of 
bone formation is controlled both by the temporal regulation and the 
level of expression of DKK1233. Trabecular bone volume is increased 
in DKK1 mutant mice and is inversely proportional to the expression 
level of this protein. Trabecular number and thickness, as well as 
cortical thickness, are also increased in the low DKK1 expressing 
genotypes524. Inhibition of DKK1 was able to reverse the bone 
destruction observed in a mouse model of arthritis and to induce new 
bone formation. TNF was identified as the key inducer of DKK1 both 
in animal models and in human RA525. Indeed, both in vitro and in 
vivo, TNF increases DKK1 expression, blocking osteoblast 
differentiation, and inhibition of DKK1 not only rescued osteoblast 
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formation but also neutralises TNF-mediated SOST expression in fully 
differentiated osteoblasts526. TNF increased the expression of 
inhibitors of the WNT signalling pathway such as DKK1 and SOST and 
could precipitate a destructive combination of low bone formation and 
high bone resorption527. Inhibitors of WNT, such as DKK1, are 
expressed in synovial fluid of RA patients, suggesting that bone 
formation is suppressed. Moreover, fully differentiated osteoblasts are 
rarely seen in arthritic bone erosions indicating that there is no major 
bone formation taking place in these lesions523. Low bone formation 
during inflammation may arise from impaired WNT signalling, which 
could also explain enhanced bone resorption, since active WNT 
signalling is associated with OPG expression227, 527. Increased DKK1 in 
rheumatoid arthritis patients treated with anti-TNF therapy was also 
associated with higher risk of progression of bone erosions 
independently of age, gender or disease activity528. It was recently 
found that DKK1 levels were correlated with markers of inflammation 
(C-reactive protein and erythrocyte sedimentation rate) and X-ray 
erosive score. Moreover, RA patients treated with anti-TNF 
(infliximab) or with IL-1Ra (anakinra) showed significantly lower 
levels of DKK1529. Ankylosing spondylitis (AS) patients have higher 
levels of DKK1 comparing with healthy individuals or patients with RA 
and psoriatic arthritis (PsA). However, DKK1 levels did not correlate 
with markers of inflammation or disease activity530-531. In a TNF 
transgenic mouse model, blockade of DKK1 had no effect on 
inflammatory sacroiliitis but reduced bone erosions and osteoclast 
number. Moreover, DKK1 blockade induced formation of 
hyperthrophic chondrocytes and fusion of the sacroiliac joints532. In 
another study, PsA patients presented higher levels of circulating 
DKK1 than healthy donors or patients with psoriasis and DKK1 levels 
were more increased in erosive PsA than in non-erosive disease533. 
On the other hand, it was reported that in caucasian women with 
more than 65 years of age enrolled in the Study of Osteoporotic 
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Fractures, high serum DKK1 levels were associated with a diminished 
risk of radiographic hip OA534.  
Like DKK1, SOST is an inhibitor of the WNT pathway. A study 
comparing bone SOST expression in AS, RA, OA and healthy 
individuals found that whereas the majority of osteocytes in healthy 
individuals and RA patients were SOST positive, the expression was 
reduced in OA patients and almost absent in AS. Moreover, the 
frequency of empty osteocyte lacunae was increased in RA patients 
compared to the other groups535. 
Recently, the WNT pathway modulator R-spondin homolog (RSPO1) 
was reported to be effective in the preservation of the joint structure 
in a TNF-tg model of arthritis. RSPO1 protected bone and cartilage by 
antagonizing DKK1 in mouse MSCs, while it induced differentiation 
and expression of OPG. Therefore, RSPO1 promotes osteoblast 
differentiation and osteoblast-mediated bone formation while blocking 
osteoclastogenesis during inflammatory arthritis.536 
In summary, the immune system has several crosstalk points with 
the skeletal system, T and B lymphocyte interact with bone cells, 
cytokine and chemokine influence bone resorption, TLR signalling is 
activated, costimulatory molecules help osteoclast differentiation and 
WNT pathway is tightly controlled by immune system related 
molecules. 
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BONE HEALING 
Bone is one of the few organs that retain the ability of regeneration in 
adult life. In fact, unlike other tissues that heal by formation of a poor 
quality scar, when a fracture occurs, bone restores all its pre-fracture 
properties.  
Fracture healing recapitulates certain aspects of skeletal development 
and growth, involving the interplay of cells, growth factors and 
extracellular matrix. Each of the four stages of bone repair, 
inflammation, soft callus formation, hard callus formation and 
remodeling, is characterized by a specific set of events, although 
there is some overlap between them (figure 11).  
 
 
Figure 11 – Cellular events of fracture healing. 
The fracture event leads to the activation of an inflammatory cascade (1), inducing 
the migration and activation of immune system cells that produce pro-inflammatory 
cytokines that recruit more immune cells and MSCs. These will then differentiate 
either in condrocytes or osteoblasts. Chondrocytes are responsible for cartilage 
synthesis and the soft callus formation (2) and osteoblasts produce bone and, 
consequently, the hard callus (3). In the final step, the newly formed bone is 
remodelled by the action of osteoclasts and osteoblasts in a coupled process (4). 
(MSC – mesenchymal stem cell) 
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At the cellular level, inflammatory cells, osteochondral progenitors 
and osteoclasts are the key players of the repair process537. Recently, 
osteal macrophages were found to be present at the injury site and to 
be required for collagen deposition and bone mineralization538. At the 
molecular level, fracture repair is mainly driven by pro-inflammatory 
cytokines and growth factors, pro-osteogenic and angiogenic 
factors539. 
Following injury, a local inflammatory reaction is triggered. 
Simultaneously, vasculature disruption occurs leading to the 
formation of a hematoma around the fracture site that becomes 
infiltrated by inflammatory cells540-541. Although the concentration of 
leukocytes in the fracture hematoma remains similar to the periphery 
for several hours after injury542, within 24 hours there is a major 
influx of cells. The predominant leukocytes that infiltrate the tissue 
are neutrophils474, which are later replaced by macrophages and T 
cells, whereas no B cells are found at any stage of fracture healing543. 
The hematoma is the source of several signalling molecules that 
induce an inflammatory cascade of cellular events that initiate 
healing544. These factors are secreted, not only by endothelial cells, 
platelets, macrophages, monocytes, but also by MSCs, chondrocytes, 
osteocytes and osteoblasts541, 545. Therefore, the hematoma contains 
cytokines and chemokines produced by the infiltrated inflammatory 
cells. Disturbance of this inflammatory phase impairs fracture 
healing. Indeed, in a rat femur fracture model the fracture hematoma 
was removed 30 minutes, 2 or 4 days after the injury, leading to a 
significant decrease in the mechanical characteristics of the new 
bone546. After inflammation, the fracture hematoma becomes 
osteogenic and angiogenic and this was demonstrated in a study 
where the transplantation of a 4-day-old hematoma into muscle 
tissue induced extraskeletal bone formation547 and angiogenesis548. A 
recent study has shown, using a mouse model of slow-healing 
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fracture, that covering the fracture with muscle cells accelerated 
healing and these cells differentiate into osteoblasts and formed bone 
nodules in vitro. Moreover, low concentrations of TNF recruited 
muscle-derived stromal cells for the fracture site, contributing for the 
initial phase of fracture healing549. Within several days of the initial 
inflammatory response, there is a sequence of events that results in 
the formation of new bone through a structure named callus. This is a 
newly developed tissue of fibrocartilage and bone that surrounds the 
fracture site545. Most fractures heal by a combination of 
intramembranous and endochondral ossification550. During the 
intramembranous ossification stage, bone is formed without the 
development of an intermediate cartilage tissue. The resulting 
structure is histologically described as hard callus551. This stage 
represents the most active period of osteogenesis and is 
characterized by high levels of osteoblast activity and  bone matrix 
mineralization537. Endochondral ossification begins with 
chondrogenesis and involves recruitment and proliferation of MSCs 
that will later originate the avascular cartilage541. The soft callus, not 
only provides mechanical support for the fracture, but also acts as a 
scaffold for the bone that will be later formed537. The second process 
of endochondral bone formation, partially overlapping with the first, is 
a sequence of events that comprises cartilage calcification and 
removal, and bone formation. Chondrocytes release enzymes, 
proteases and phosphatases, which degrade proteoglycans and 
provide phosphate ions that precipitate in the extracellular matrix 
and, together with calcium released by mitochondria of hypertrofic 
chondrocytes, mineralize the cartilage541. Condrocytes undergo 
apoptosis and chondroclasts are formed and activated to resorb the 
mineralized cartilage matrix, which sends signals to enable 
vascularization of the newly formed tissue552. During the final stage, 
MMPs degrade cartilage and bone, allowing infiltration of blood 
vessels551. The differentiation and activity of osteoblasts allows the 
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replacement of the calcified matrix with woven bone541, 552. The last 
stage of fracture repair is the replacement of the newly formed woven 
bone by the definitive tissue, the lamellar bone, and restoration of 
the normal vascular supply. BMUs require 1 to 4 years to replace 
woven by lamellar bone. The callus is then reshaped mainly by the 
action of osteoclasts that act to remodel the external surface of 
bone541. 
Although local controlled inflammation is essential for bone repair, 
evidence has shown that increased or prolonged inflammation within 
the fracture hematoma impairs fracture healing540. In a study, 
inflammation was induced by lypopolysaccharide (LPS) injection in 
rats with femur fractures. LPS is known to be a potent trigger of the 
inflammatory response and was administrated either locally at the 
site of fracture, or systemically by intraperitoneal injection. Both 
forms of administration led to larger but more immature callus 
production, with reduced bone mineral content (BMC) and BMD, 
suggesting that increased callus production appears to compensate 
for immaturity. Moreover, systemic administrated LPS reduced 
mechanical strength553. In another study, rats treated with anti-
neutrophil serum showed decreased cartilaginous tissue markers such 
as SRY (sex determining region Y)-box 9 (SOX9) and type II collagen, 
along with increased expression of OCL and RUNX2474. Therefore, one 
can speculate that high neutrophil counts and neutrophil priming, 
leading to an increased influx of cells into the fracture hematoma, 
play an important role in the pathogenesis of impaired fracture 
healing after systemic inflammation. These findings suggest that 
neutrophils may stimulate chondrogenesis and inhibit osteogenesis 
and prolonged influx of neutrophils into the fracture hematoma during 
systemic inflammation may indeed impair fracture healing through 
stimulation of chondrogenesis. On the other hand, monocytes can 
differentiate towards several types of macrophages depending on the 
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environmental circumstances. IFN-γ and LPS exposure induces a 
classically activated proinflammatory phenotype, while the 
regenerative phenotype is triggered by IL-4 or IL-13554-555. In 
addition, it has been shown that severe injury induces T cell 
unresponsiveness, characterized by both reduced proliferation and IL-
2 production556. These findings indicate that unresponsiveness of T 
cells during systemic inflammation may also contribute to reduced 
osteogenesis after systemic inflammation. On the other hand, 
absence of γ/δ T cells improved fracture healing in vivo, through 
increased expression of bone and cartilage matrix proteins, as well as 
BMP-2 at a critical reparative phase. The result was improved stability 
at the repair site and an overall better biomechanical strength557. In 
summary, systemic inflammation induces several changes in 
leukocyte characteristics such as neutrophil priming, altered 
monocyte differentiation, T cell anergy and increased γ/δ T cell 
activation that influence bone healing.  
Mononuclear cells and cell-free fluids from experimental wounds have 
shown to have immunosuppressive properties. Several cytokines 
were upregulated in a time-dependent manner in the fracture 
hematoma; IL-10 peaked in the first 24 hours after fracture, IL-6 in 
the first 48 hours, IL-8 after the first 48 hours and IL-12 on days 4-7. 
IL-6, IL-8, IL-10 and IL-12 levels could even be detected in the 
plasma of injured patients558. Indeed, cellular components, 
particularly the immune cell population of the fracture hematoma, 
changes very quickly within hours after fracture542. In order to better 
understand the cellular and molecular events in the initial phase of 
fracture healing, several studies have used animal models to evaluate 
the expression pattern during this process. IL-1, IL-6 and TNF are 
secreted by inflammatory cells and act as chemotactic factors for the 
recruitment of other inflammatory cells and MSCs. Tsangari et al 
studied a cohort of patients that suffered a fragility fracture of the 
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femoral neck, and showed that the expression of IL-6 and 
RANKL/OPG ratio was increased in fracture patients as compared with 
age-matched controls. IL-6 mRNA expression correlated with RANKL, 
which reinforced the concept that IL-6 induces RANKL mRNA 
expression in osteoblasts559. In addition, studies in IL-6 knockout 
mice have shown that there was a delay in callus formation and lower 
osteoclast density560. IL-1β has a paradoxical effect, as it is 
upregulated in response to the fracture event, but in IL-1β knockout 
mice there is no change in callus formation and bone and cartilage 
matrix production561. On the other hand, in the absence of TNF 
signaling, there was a 2-4 days delay in chondrogenic differentiation 
and a 2-3 weeks delay in endochondral tissue resorption562. The 
expression of RANKL, OPG and M-CSF is increased after initial injury 
and later during the period of mineralized cartilage resorption. On the 
contrary, during the bone formation phase, RANKL, OPG and M-CSF 
are downregulated563. SOX9 is a key transcription factor for 
chondrogenesis that is expressed in the callus, together with RUNX1 
and RUNX2. These transcription factors appear at an early fracture 
repair response and SOX9 is modulated by the mechanical 
microenvironment, influencing the fate decision between osteogenic 
and chondrogenic lineage commitment564. 
Platelets release platelet-derived growth factor (PDGF) and TGFβ play 
a role in initiating fracture repair by contributing for MSCs migration, 
activation and proliferation, angiogenesis, chemotaxis of 
inflammatory cells and further aggregation of platelets565. TGFβ is 
produced by osteoblasts and chondrocytes and induces the 
production of matrix proteins such as collagen, proteoglycans, OPN, 
osteonectin and ALP. FGFs are synthesized by immune cells, MSCs, 
osteoblasts and chondrocytes. These factors induce growth and 
differentiation of several cells, such as fibroblasts, myocytes, 
osteoblasts and chondrocytes. FGFs are present during the early 
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stages of fracture repair where they play a crucial role in 
angiogenesis and MSCs proliferation566. Simultaneously, BMPs 
released by osteoprogenitor cells, osteoblasts and bone matrix induce 
the differentiation of MSCs into chondrocytes and osteoblasts, and 
osteoprogenitor cells into osteoblasts551, 565. Although BMPs are 
structurally and functionally related with each other, they present 
different temporal patterns of expression at different stages of 
fracture healing551. BMP-2 shows maximal expression within 24 hours 
of injury and its expression levels are maintained, suggesting that 
this factor is involved in initial callus formation567. In fact, in the 
absence of BMP-2, MSCs at the repair site do not differentiate and 
fracture healing is impaired568. On the other hand, expression of BMP-
3, -4, -7 and -8 is restricted to the stage of calcified cartilage 
resorption and active osteoblastic recruitment. BMP-5 and -6 have a 
regulatory effect on both intramembranous and endochondral 
ossification and therefore, their expression is maintained from day 3 
until day 21 post-fracture550, 567. BMPs may also stimulate the 
synthesis and secretion of other bone and angiogenic growth factors, 
such as vascular endothelial growth factor (VEGF) and IGF-I. IGF-I 
promotes bone matrix formation by inducing synthesis of type I 
collagen and noncollagenous matrix proteins by osteoblasts. IGF-II 
acts at a later stage of endochondral bone formation where it 
stimulates type I collagen production and cartilage matrix 
synthesis551. OPN, an extracellular matrix protein, plays an important 
role in angiogenesis and osteoclastic bone remodeling, two vital 
processes for bone healing. OPN deficiency in vivo altered but did not 
prevent bone healing and remodeling of fractures. The presence of 
OPN is essential for normal early callus formation, neovascularization 
and biomechanical strength and ductility. Moreover, OPN deficiency 
delayed the time-course of the remodeling phase in late stage 
healing569. Macrophage migration inhibitory factor (MIF) is a potent 
proinflammatory cytokine involved in the inflammatory response and 
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its expression was reported to be upregulated during fracture healing 
in rats. MIF deficiency in a tibia fracture model showed worse 
mechanical behaviour, mainly due to increased osteoid volume, and 
delay in its mineralization within the fracture callus. These mice also 
presented lower number of osteoclasts, as well as suppression of 
MMPs, CTSK and ALP570.  
Some experimental studies made an effort to relate temporal gene 
expression with the sequence of events of bone healing. In a work 
with Sprague-Dawley rats, the gene expression on days 3 and 11 
post-fracture was evaluated. The authors showed that different 
molecular pathways of gene expression regulate different phases of 
bone healing. At day 3 there was a predominance of cell proliferation 
and protein metabolism genes, as required for the proliferation of the 
periosteal mesenchymal cells of the soft callus. On the other hand, 
genes that predominated at day 11 were consistent with maturation 
of the callus during endochondral bone formation571. In C57bL/6 mice 
it was observed that the inflammatory cluster of genes was expressed 
from day 1 post-fracture until day 5. Chondrogenic phase started at 
day 4 and was prolonged for 7 days; finally, the remodeling phase 
started on day 10 post-fracture and was prolonged at least until day 
21572. 
The contribution of the WNT/β-catenin pathway to fracture healing 
depends on the function of β-catenin in the different stages of 
fracture repair, namely in the commitment and regulation of 
osteoblasts573. Moreover, an in vivo study showed that the WNT 
pathway members (WNT5A, FZ2 and β-catenin) and the target genes 
[fibronectin, connexin 43, periostin (OSF-2) and retinoic acid receptor 
γ (RARG)] were upregulated in the fracture site. They also assessed 
other pathway members [WNT4A, WNT5B, dishevelled (DVL)1-3, 
TCF, LEF and LRP5] as well as target genes [homeobox protein 
88 
 
engrailed-1 (EN-1), PPARδ and CD44] and found increased levels in 
the fractured bones, particularly at 5 days after fracture, when active 
bone and cartilage formation was occurring. The only exception was 
the transcription factor LEF, which was found downregulated between 
days 3 and 14, coinciding with the peak of osteoblast 
differentiation574. Since LEF inhibits RUNX2-dependent activation of 
OCL it is not surprising that this transcription factor is downregulated 
during fracture repair575. As healing progresses, at 21 days post 
fracture, the process of intramembranous ossification slows down and 
LEF expression is restored to the levels found in intact bone574. 
Therefore, the authors suggest a role for WNTs in the early stages of 
healing that involve intramembranous bone formation. The 
importance of WNT/β-catenin signaling was also reported by other 
groups573, 576. Tissue-specific inactivation of β-catenin in committed 
osteoblasts led to a significant reduction in calcified callus formation, 
along with incomplete bone bridging across the fracture gap. On the 
other hand, overexpression of β-catenin in committed osteoblasts 
enhanced fracture healing573, 577. Loss of the negative regulator axin2, 
a protein from the adenomatous polyposis coli (APC) complex that 
stabilizes β-catenin in the cytoplasm, results in prolonged 
amplification of the WNT signal and, consequently, on increased 
proliferation rate at the injury site. When WNT was supplied to the 
injury site after the initial inflammatory period, cells proliferated and 
accelerated their differentiation into osteoblasts and, consequently, 
stimulated bone healing578-579. 
Three recent studies analyzed the effect of DKK1 on bone healing in 
skeletally mature mice. Administration of DKK1 to the fracture site 
reduced β-catenin levels and inhibited chondrogenesis during the first 
week after fracture by blunting the expression of SOX9 and RUNX2. 
The fracture failed to heal and the injury site contained 
undifferentiated mesenchymal-like tissue573. In another report, DKK1 
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prevented activation of the WNT/β-catenin pathway during the first 
week of healing and reduced bone regeneration by 84%. DKK1 did 
not restrain angiogenesis or induce cell death at the repair site but 
suppressed the expression of osteogenic genes, specifically RUNX2580. 
A third report showed that DKK1 serum levels were increased during 
the second week of fracture healing, suggesting that DKK1 might be 
involved in slowing the anabolic response at later stages of bone 
repair576. Only one study in young mice has addressed the expression 
levels of SOST during fracture repair and they found that this protein 
was downregulated during the process581. In two recent studies, 
administration of a SOST monoclonal antibody in both rat and 
monkey models of fracture healing significantly increased bone mass 
and strength at the site of fracture. In monkeys, ten weeks after 
fracture, in the SOST antibody group callus presented less cartilage 
and smaller fracture gaps, containing more bone and fibrovascular 
tissue582-583. Overall, these data demonstrate the central role of β-
catenin in orchestrating the cellular events that mediate fracture 
repair. DKK1 and SOST prevent the early stages of bone repair by 
blocking WNT/β-catenin signaling and the differentiation of MSCs into 
chondrocytes or osteoblasts577. 
The management of fragility fractures associated with osteoporosis is 
difficult due to several factors including inadequate fixation strength 
of implants used to stabilize the fracture until bone union occurs. In 
particular, the fragility fractures affecting the metaphyseal region of 
long bones are associated with an increased rate of complications. 
Several studies report nonunion in 2-10%, malalignment after 
surgery in 4-40%, metal work failure in 1-10%, and reoperation in 3-
23% of the cases584. Experimental studies have shown that the 
decline in the capacity for fracture repair is age related. Disturbance 
of the full redevelopment of mechanical strength within fracture 
calluses in the elderly has been shown in experimental rat models585-
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586. In humans, it is possible that fracture healing is affected by 
aging, particularly in the elderly osteoporotic patients587. In a study it 
was described that in 6, 26 and 52 weeks old rats, there is a delay in 
radiographic progression of fracture healing upon aging but the 
expression of the key genes involved in this process is not age-
dependent 584, 588-589. Moreover, in another work the authors found 
age-related changes translated in delay in cell differentiation, 
decrease in bone formation, delay in angiogenesis and impairment of 
bone remodeling. However, they observed that the amount of 
cartilage formed in the fracture site was not affected by age590. While 
resorption augments with age, formation decreases, possibly due to 
lower number of osteoblasts591. Osteoblasts originate from MSCs that 
reside in the periosteum and bone marrow, together with 
hematopoietic stem cells. These two stem cell types cooperate with 
each other through direct cell-cell interactions; however, bone 
marrow environment changes with age resulting in unfavorable 
stimuli towards differentiation into osteoblasts. As an end result, total 
marrow fat increases with age and there is an inverse relationship 
between marrow adipocytes and osteoblasts with aging592. 
Bone turnover markers are widely used to monitor the course of 
callus consolidation during bone healing. Their levels vary throughout 
the course of fracture repair with changing rates dependent on the 
size of the fracture and the time it takes to heal. In a longitudinal 
study where the serum levels of biochemical markers associated with 
bone metabolism were assessed before, during and after fracture 
repair, the authors showed that a few hours after fracture there were 
no changes in bone turnover markers when compared to the levels 
measured before fracture. In opposition, markers of bone formation 
and resorption were significantly increased four months after fracture 
and bone turnover remained elevated up to 12 months after 
fracture593. In another study, authors observed that ALP levels 
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increased only one week after surgery while bone resorption markers 
were increased immediately after fracture. Overall, bone turnover 
markers reached their peak values at 3-5 weeks after fracture, 
reflecting remodeling during the healing process594. Inhibition of 
osteoblast synthesis occurs after fracture, as shown by decreased 
levels of bone specific ALP and P1CP in the immediate post-fracture 
period. On the other hand, OCL was reported to be increased at this 
time and it is hypothesized that this represents the release of OCL 
from its bone-bound form595. The role of osteoclast in bone healing is 
somewhat controversial. In an in vivo study in sheep, authors found 
that resorption takes place in an early phase of fracture healing as 
observed by an increase in osteoclast density in the first six weeks 
after fracture. The authors hypothesized that osteoclasts not only 
resorb bone but they participate in the overall healing mechanism by 
maintaining and improving the structural strength of bone tissue596. 
This early phase healing was also measured in patients with tibial 
shaft fracture by bone turnover markers in order to identify patients 
with normal or delayed healing597. The authors found that in the first 
week after fracture, CTX levels decreased dramatically in the cases of 
delayed healing. By the fourth and eight weeks, the changes 
observed were a reduction in the value of TRAcP5b, whereas no 
changes were identified in the levels of ALP or P1NP598. 
The interplay between fracture healing and inflammation, highlight 
once more bone and immune system close relationship599-601.  
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The present work aims to address the interaction between skeletal 
and immune systems through the study of the effect of inflammation 
on bone biological, structural and mechanical behavior. 
 
The specific aims of this work are: 
I. Address to what extent biomechanical properties of bone are 
influenced by arthritis in an animal model; 
II. Study the influence of arthritis on the trabecular bone collagen 
network in an animal model; 
III. Compare bone gene expression between RA and primary OP 
patients, matched for BMD and major clinical fracture risk 
factors; 
IV. Study the profile of genes involved in inflammation and bone 
remodeling during the three major steps of the early phase of 
callus formation in human bone after a hip fragility fracture. 
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In agreement with the Decreto-Lei 388/70, art. 8º, the results 
presented and discussed in this thesis were published or submitted 
for publication in the following scientific peer-reviewed journals: 
 
I. Caetano-Lopes J*, Nery AM*, Henriques R, Canhão H, Duarte 
J, Amaral PM, Vale M, Moura R, Pereira PA, Weinmann P, 
Abdulghani S, Souto-Carneiro M, Rego P, Monteiro J, Sakagushi 
S, Viana Queiroz M, Konttinen YT, Graça L, Vaz MF, Fonseca JE. 
Chronic arthritis induces quantitative and qualitative bone 
disturbances leading to compromised biomechanical properties. 
Clinical and Experimental Rheumatology 2009, 27(3):475-482 
(*Caetano-Lopes J and Nery AM contributed equally for this work) 
 
II. Caetano-Lopes J, Nery AM, Canhão H, Duarte J, Cascão R, 
Rodrigues A, Perpétuo IP, Abdulghani S, Amaral PM, Sakaguchi 
S, Konttinen YT, Graça L, Vaz MF, Fonseca JE. Chronic arthritis 
leads to disturbances in the bone collagen network. Arthritis 
Research and Therapy 2010 15; 12(1):R9 
 
III. Caetano-Lopes J, Rodrigues A, Lopes A, Vale AC, Pitts-Kiefer 
MA, Vidal B, Perpétuo IP, Monteiro J, Konttinen YT, Vaz MF, 
Nazarian A, Canhão H, Fonseca JE. Rheumatoid arthritis bone 
fragility is associated with increased DKK1 expression and 
disturbances in the bone turnover regulating genes. Submitted 
for publication in May 2011. 
 
IV. Caetano-Lopes J, Lopes A, Rodrigues A, Fernandes D, 
Perpétuo IP, Monjardino T, Lucas R, Monteiro J, Konttinen Y, 
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Canhão H#, Fonseca JE#. Upregulation of Inflammatory Genes 
and Downregulation of Sclerostin Gene Expression Are Key 
Elements in the Early Phase of Fragility Fracture Healing. PLoS 
ONE 2011 6(2): e16947. doi:10.1371/journal.pone.0016947 
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Chronic arthritis induces quantitative and qualitative bone 
disturbances leading to compromised biomechanical 
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Chronic arthritis leads to disturbances in the bone collagen 
network 
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PART III 
 
 
Rheumatoid arthritis bone fragility is associated with 
increased DKK1 expression and disturbances in the bone 
turnover regulating genes 
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Upregulation of Inflammatory Genes and Downregulation of 
Sclerostin Gene Expression Are Key Elements in the Early 
Phase of Fragility Fracture Healing 
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It is well established that in certain inflammatory conditions bone 
remodeling is disturbed, shifting the balance towards bone resorption, 
which ultimately leads to the development of secondary osteoporosis. 
However the interaction between immune and skeletal systems can 
also have a beneficial effect when after a fracture inflammation 
triggers the healing cascade. The aim of this dissertation thesis was 
to understand the effect of inflammation on bone structural, 
mechanical and biological behavior.   
The first study of this thesis (part I) focused on the analysis of the 
direct effect of chronic inflammation on bone biomechanical behavior. 
In part II we studied the effect of inflammation on collagen 
metabolism and organization and found that the bone weakening 
effect of arthritis was due to high bone turnover and disorganized 
collagen type I matrix. Following these initial animal model 
observations, the first to describe a direct effect of arthritis on 
collagen structure and bone biomechanics, we confirmed and further 
detailed these observations in human RA bone, assessed by bone 
microenvironment gene expression, microCT structure analysis and 
bone mechanics. We have identified DKK1 as a major potential 
regulatory factor of bone disturbances in RA, suggesting that this 
could be an interesting target for future treatment interventions. 
Finally, we have used the post-fracture inflammatory reaction as a 
model for characterizing the kinetics of inflammatory and bone 
remodeling related genes (part IV). Our results indicate that the 
expression of inflammation-related genes, especially IL-6, is highest 
at the very first days after fracture but from day 4 onwards there is a 
shift towards bone remodeling genes, suggesting that the 
inflammatory phase triggers bone healing. We propose that an initial 
inflammatory stimulus and a decrease in sclerostin-related effects are 
the key components in fracture healing. Therefore local promotion of 
155 
 
these events might constitute a promising medical intervention to 
accelerate fracture healing. 
It is relevant to emphasize that the animal model that we have used 
is the most similar to human RA. In fact, SKG mice develop a 
rheumatoid factor positive, erosive chronic polyarthritis that affects 
both large and small joints and present some of the systemic features 
of RA such as interstitial pneumonitis with various degrees of 
perivascular and peribronchiolar cellular infiltration, infiltration of 
inflammatory cells in the skin and subcutaneous rheumatoid-like 
nodules. The SKG mice have a BALB/c background with a single 
recessive point mutation in the zeta-chain-associated protein kinase 
70 (ZAP-70) gene, a GC substitution that alters codon 163 from 
tryptophan to cystein602. In our study group, penetrance of arthritis 
was of 100%, as evaluated by a semiquantitative arthritis score. In 
femoral and vertebral bone we have used standard mechanical tests 
to assess osteoporotic bone and for the test of new anti-osteoporotic 
drugs603. When an increasing force is applied to bone it leads first to 
a fully elastic deformation so that if the force is released the structure 
will assume its former shape. This property of the bone is translated 
by its stiffness. When more stress is applied, bone tissue starts to 
undergo microfractures and truly irreversible plastic changes occur. 
For vertebrae, compression tests were used, while 3-point bending 
was the appropriate for femurs and all tests were corrected for the 
size of the specimen. Analysis from the stress-strain curves have 
shown that bones from mice with arthritis have impaired elasticity, 
ductility and ultimate fracture strength when compared with bones 
from BALB/c mice that do not develop arthritis.  
The results obtained by the biomechanical tests were sustained by 
the findings of bone structure obtained by SEM, which enables the 
observation of tissue topography through high-resolution images and 
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has proven effective in investigating the activity states of bone 
surfaces83-84. In SKG mice there was less trabecula-occupied area, 
increased distance between trabeculae and decreased trabecular and 
cortical thickness than in control mice, consistent with increased bone 
fragility induced by arthritis. In addition, we assessed the collagen 
network in these mice through multiphoton microscopy and by 
biochemical turnover markers. Multicolour non-linear microscopy of 
type I collagen was analyzed using SHG and TPE in the backward and 
forward SHG mode. The backward-SHG channel detects the 
backscattered SHG signal and the forward-SHG channels receives the 
photons that are transmitted through the sample105. Forward-to-
backward signal ratio reflects collagen matrix organization and 
density and a higher ratio is associated with a less dense matrix103. 
Moreover, a study in collagen fibril from tendon samples suggested 
that the forward-SHG channel translates essentially the mature 
polymerized collagen and the backward-SHG channel represents the 
immature collagen fibril segments, indicating ongoing 
fibrilogenesis106. In this work we found that vertebral body trabecular 
bone from SKG animals have a higher forward-to-backward ratio 
reflecting lower density and organization of collagen fibrils than the 
healthy control bone. Moreover, multiphoton microscopy images 
disclosed a disturbed organization of fiber bundles in arthritic bone 
compared with the organized lamellar architecture of healthy bone. 
Although two studies have assessed collagen density and organization 
on bone102-103, this was the first report to address the disorganized 
collagen matrix in the context of arthritis. On the other hand, 
formation and degradation of bone matrix can be monitored by 
cleavage products of collagen metabolism that pass into the 
circulation and/or are excreted in the urine and can be used as 
markers of bone turnover31. In the fibril assembly phase, de novo 
synthesis of collagen leads to release of collagen propeptides P1NP 
and P1CP. On the other hand, osteoclasts resorb the matrix through 
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the action of CTSK leading to the release of cross-linked telopeptides, 
NTX and CTX32. Results have shown that both P1NP and CTX are 
increased in SKG animals depicting higher bone remodeling rate. 
Collagen metabolism is relevant for bone biomechanics at two levels. 
First of all, collagen fiber orientation determines the deposition of 
hydroxyapatite crystals (stiffness) in the extracellular matrix, directly 
influencing the elasticity of bone. Secondly, collagen fibers per se 
directly determine the ability to absorb energy through plastic 
deformation, thus determining ductility and ultimately fracture 
strength604. Therefore, the high remodeling rate of collagen might be 
associated with decreased bone mineralization that may reduce its 
stiffness and ductility.  
As observed in the SKG mice model, results from the compression of 
trabecular cylinders extracted from femoral epiphysis of RA patients 
reflect impairment of biomechanical behavior, particularly strength 
and stiffness. We have detailed the implications of these observations 
through an evaluation of gene expression of bone microenvironment. 
We have found that genes that code for pro-inflammatory cytokines 
were upregulated in RA patients, particularly IL-17, which plays an 
important role in stimulating osteoclastogenesis. In accordance, 
RANKL/OPG expression ratio was increased in RA. Overall osteoclast 
gene expression was similar between RA and primary OP patients, 
with the exception of β3 subunit of αvβ3 integrin, which was lower in 
RA patients, suggesting an intriguing disturbance in osteoclast 
adherence to bone matrix138. RA patients had an upregulation of OSX, 
which together with increased FGF2 and IGF-I, might represent a 
compensatory mechanism for osteoblastic activity response that have 
been previously observed in a mice model of arthritis605. 
Interestingly, OSX is involved in DKK1 induction222, which is coherent 
with our observation of an increase in this gene expression in the 
bone of RA patients. In addition, DKK1 has a high affinity for LRP6 
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and induces its accumulation both at the cell surface and in 
endosomes606 and in fact our observations showed that increased 
expression of DKK1 in RA was paralleled by an upregulation of LRP6. 
DKK1 upregulation in RA patients is limiting the effects of the pro-
osteoblastic factors, as can be inferred by the low collagen expression 
in RA bone. Therefore, RA bone microenvironment has a gene 
expression profile characterized by upregulated pro-osteoclastogenic 
cytokines and DKK1, increased RANKL/OPG expression ratio, 
paralleled by raised expression of factors that promote osteoblastic 
activity. The marked DKK1 expression observed in RA patients might 
limit this tentative repairing effort through osteoblastic activity, as 
suggested by the low type I collagen expression. Bone loss in chronic 
inﬂammatory diseases thus appears to result from enhanced bone 
resorption and impaired bone formation, which constitutes a 
detrimental imbalance of bone remodeling and precipitates the rapid 
loss of bone mass in the course of inﬂammatory disease. 
Differences were observed in gene expression between RA bone and 
established primary OP bone in spite of the fact that these two 
patient groups were matched for BMD and major fracture risk factors 
and had similar bone microarchitecture and biomechanics properties. 
These observations might indicate that the differences in gene 
expression that were observed reflect biologically specific 
mechanisms responsible for bone fragility in RA. Of interest, RA 
patients had a relatively short disease duration, low erosive rate and 
low microstructural damage (as evaluated by microCT) reinforcing the 
idea that these differences in gene expression occurred in the 
absence of major clinically meaningful bone damage in RA. 
Unlike the unregulated and prolonged inflammation seen in RA, 
fracture healing is a highly regulated and brief process mainly 
characterized by altered levels of TNF, IL-1, and IL-6551. In 
accordance with this we observed that cytokine gene expression was 
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more pronounced during the first days after fracture and specifically 
the decrease in IL-6 expression levels was far more pronounced than 
what was observed with the other pro-inflammatory cytokines 
evaluated. In fact, this is in line with a previous observation in which 
IL-6 ablation during fracture healing significantly reduced 
osteoclastogenesis and impaired callus formation607. Paralleling this 
cytokine rise, OPG expression diminished gradually after fracture, 
releasing the inhibitory signal for osteoclast differentiation. 
Concordantly, RANKL peaked at 4th-7th day after trauma, creating a 
stimulus for osteoclast differentiation from its precursors. We found 
that osteoclast-specific genes were significantly increased from day 8 
onwards after fracture, pointing to an activation of osteoclast 
function. Specifically, CTSK values were increased from the 8th day 
post fracture onwards, indicating that during 4-7 days after fracture, 
osteoclastogenesis stimulus was ongoing intensively, allowing that by 
day 8 osteoclasts containing CTSK had already been formed in 
relatively high numbers. The active role of osteoclasts during the 
early phase of fracture healing was already described in a sheep 
model, where it was proposed that these cells not only resorb bone 
but adjust the system, together with osteoblasts, in order to improve 
bone strength596. Concerning osteoblast differentiation and activity, 
RUNX2 increased from the initial phase of bone healing, whereas OSX 
increased after 4 days post-fracture sustaining the evidence that OSX 
acts later than RUNX2 in osteoblast lineage commitment222. SOST 
expression decreased significantly from the beginning of the healing 
cascade, in a parallel way to IL-6 decrease, suggesting that there is 
an initial blockage of osteoblast proliferation and differentiation that 
is subsequently released over the period of fracture healing, which is 
in accordance with a study in young mice581. In addition, in a closed 
femoral fracture model in rats and a fibular osteotomy model in 
cynomolgus monkeys, treatment with anti-SOST antibody 
significantly enhanced fracture healing by improvement of bone 
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formation, bone mass and bone strength608. Taken together, these 
observations are highly suggestive of the existence of a two step 
process in bone healing, dependent on an initial inflammatory 
stimulus and a latter decrease in SOST-related effects. Therefore 
local promotion of these sequential events constitutes a medical 
intervention that worth to be tested in fracture healing. 
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Chronic inflammation has a harmful effect upon bone. Inflammatory 
cells express high levels of RANKL and secrete pro-inflammatory 
cytokines, which activate osteoclast differentiation and increase bone 
resorption. On the other hand, there is also an increase in pro-
osteoblastogenic factors that try to compensate this destructive 
effect. However, this feedback mechanism is hampered by the 
osteoblast inhibition imposed by DKK1. The net effect is an impaired 
bone matrix organization, which leads to an inadequate 
mineralization and altered structural properties of collagen. This 
constitutes the main cause of the deterioration of bone mechanical 
properties and consequent bone fragility observed in RA.  
Although it might seem paradoxical, these same proinflammatory 
factors orchestrate the sequence of events that promote bone 
fracture healing, balancing osteoclastic activity, sclerostin expression 
and osteoblastic activity.  
The work herein discussed clearly shows that inflammation has a 
complex role in bone regulation. The identification of key regulators 
of this system will be crucial for the future management of both RA 
and fracture healing. 
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